Probe for ultrasound tissue treatment

Information

  • Patent Grant
  • 11207547
  • Patent Number
    11,207,547
  • Date Filed
    Friday, December 18, 2020
    3 years ago
  • Date Issued
    Tuesday, December 28, 2021
    2 years ago
Abstract
A method and system for providing ultrasound treatment to a tissue that contains a lower part of dermis and proximal protrusions of fat lobuli into the dermis. An embodiment delivers ultrasound energy to the region creating a thermal injury and coagulating the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. An embodiment can also include ultrasound imaging configurations using the same or a separate probe before, after or during the treatment. In addition various therapeutic levels of ultrasound can be used to increase the speed at which fat metabolizes. Additionally the mechanical action of ultrasound physically breaks fat cell clusters and stretches the fibrous bonds. Mechanical action will also enhance lymphatic drainage, stimulating the evacuation of fat decay products.
Description
BACKGROUND
Field of the Invention

The present invention relates to ultrasound therapy systems, and in particular to a method and system for treating cellulite.


Description of the Related Art

Cellulite is a common skin disorder that appears as an irregularity of skin contour, often characterized by a dimple appearance of the skin. This condition affects 80% of women worldwide and tends to gather superficially around the thighs, hips, and buttocks.


Cellulite develops in the body when fat is deposited immediately below the dermis and contained in fat chambers (lobuli) that can become swollen. As the fat cells grow in size, lobuli tend to protrude into a dermis layer, surrounding tissue becomes compressed and hardened, making blood circulation more difficult in trapping fluids. Reduced elasticity of the adipose tissue produces an undesirable tension between the layers. The resulting protrusions and depressions of connective tissue anchor points create the appearance of cellulite.


This condition responds with varying results to invasive procedures, such as liposuction. The non-invasive technologies such as massagers, and low frequency ultrasound diathermy, show marginal results. Preliminary results shown by combination of infrared light and RF energy have some promise of improving skin contours, but significant progress is needed.


SUMMARY

In accordance with various aspects of the present invention, a method and system for non-invasive treatment of cellulite with ultrasound are provided. An exemplary treatment method and system comprises a therapeutic ultrasound system for providing ultrasound treatment to a deep tissue region that contains a lower part of dermis and proximal protrusions of fat lobuli into the dermis. Such an exemplary treatment system delivers conformal ultrasound therapeutic energy to the region creating a thermal injury and coagulating the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis the dermis resulting in improved appearance of the overlaying superficial layers of the skin. In accordance with exemplary embodiments, an exemplary treatment system may include ultrasound imaging mechanisms using the same or a separate probe before, after or during the treatment. Other imaging configurations can be utilized to image, monitor, and provide feedback of ultrasound therapy, such as MRI, X-Ray, PET, infrared or others.





BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter of the invention is particularly pointed out in the concluding portion of the specification. The invention, however, both as to organization and method of operation, may best be understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals:



FIG. 1 illustrates a block diagram of an exemplary ultrasound treatment system for treating cellulite in accordance with an exemplary embodiment of the present invention;



FIG. 2 illustrates a cross sectional diagram of an exemplary probe system in accordance with exemplary embodiments of the present invention;



FIGS. 3A and 3B illustrate block diagrams of an exemplary control system in accordance with exemplary embodiments of the present invention;



FIGS. 4A and 4B illustrate block diagrams of an exemplary probe system in accordance with exemplary embodiments of the present invention;



FIG. 5 illustrates a cross-sectional diagram of an exemplary transducer in accordance with an exemplary embodiment of the present invention;



FIGS. 6A and 6B illustrate cross-sectional diagrams of an exemplary transducer in accordance with exemplary embodiments of the present invention;



FIG. 7 illustrates exemplary transducer configurations for ultrasound treatment in accordance with various exemplary embodiments of the present invention;



FIGS. 8A and 8B illustrate cross-sectional diagrams of an exemplary transducer in accordance with another exemplary embodiment of the present invention;



FIG. 9 illustrates an exemplary transducer configured as a two-dimensional array for ultrasound treatment in accordance with an exemplary embodiment of the present invention;



FIGS. 10A-10F illustrate cross-sectional diagrams of exemplary transducers in accordance with other exemplary embodiments of the present invention;



FIG. 11 illustrates a schematic diagram of an acoustic coupling and cooling system in accordance with an exemplary embodiment of the present invention; and



FIG. 12 illustrates a block diagram of a treatment system comprising an ultrasound treatment subsystem combined with additional subsystems and methods of treatment monitoring and/or treatment imaging as well as a secondary treatment subsystem in accordance with an exemplary embodiment of the present invention.





DETAILED DESCRIPTION

The present invention may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, the present invention may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions under the control of one or more control systems or other control devices. In addition, the present invention may be practiced in any number of medical contexts and that the exemplary embodiments relating to a non-invasive cellulite treatment system as described herein are merely indicative of exemplary applications for the invention. For example, the principles, features and methods discussed may be applied to any medical application. Further, various aspects of the present invention may be suitably applied to other applications.


In accordance with various aspects of the present invention, a non-invasive method and system for treating cellulite are provided. For example, in accordance with an exemplary embodiment, with reference to FIG. 1, an exemplary treatment system 100 configured to treat a region of interest 106 comprises a control system 102, an imaging/therapy probe with acoustic coupling 104, and a display system 108.


Control system 102 and display system 108 can comprise various configurations for controlling probe 104 and overall system 100 functionality, such as, for example, a microprocessor with software and a plurality of input/output devices, system and devices for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or transducers, and/or systems for handling user input and recording treatment results, among others. Imaging/therapy probe 104 can comprise various probe and/or transducer configurations. For example, probe 104 can be configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, or simply a separate therapy probe and an imaging probe.


In accordance with an exemplary embodiment, treatment system 100 is configured for treating a deep tissue region that contains a lower part of dermis and proximal protrusions of fat lobuli into the dermis, by first, imaging of region of interest 106 for localization of the treatment area and surrounding structures, second, delivery of ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect, and third to monitor the treatment area before, during, and after therapy to plan and assess the results and/or provide feedback. As to the delivery of energy, control system 102 and transducer system 102 can be suitably configured to deliver conformal ultrasound therapeutic energy to ROI 106 creating a thermal injury and coagulating the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. As used herein, the term “dermis” refers to any part of the dermis and/or the epidermis.


In addition, by treatment of ROI 106, transducer system 102 may be configured to deliver one or more energy fields to promote one or more effects, for example, ablation of existing tissue, the breaking up of fat cell clusters, stretching of the fibrous bonds, enhancement of lymphatic drainage, stimulation of the evacuation of fat decay products, and/or enhanced cell permeability in order to treat cellulite.


An exemplary ultrasound therapy system of FIG. 1 is further illustrated in an exemplary embodiment in FIG. 2. A therapy transducer system 200 includes a transducer probe 202 connected to a control system 204, and display 206, in combination may provide therapy, imaging, and/or temperature or other tissue parameters monitoring to region of interest 210. Exemplary transducer system 200 is configured for first, imaging and display of region of interest 210 for localization of the treatment area and surrounding structures, second, delivery of focused, unfocused, or defocused ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect of thermal ablation to treat cellulite, and third to monitor the treatment area and surrounding structures before, during, and after therapy to plan and assess the results and/or provide feedback to control system 204 and/or an operator.


Exemplary transducer probe 202 can be configured to be suitably controlled and/or operated in various manners. For example, transducer probe 202 may be configured for use within an ultrasound treatment system, an ultrasound imaging system and/or an ultrasound imaging, therapy, and/or treatment monitoring system, including motion control subsystems.


Control system 204 can be configured with one or more subsystems, processors, input devices, displays and/or the like. Display 206 may be configured to image and/or monitor ROI 210 and/or any particular sub-region within ROI 210. Display 206 can be configured for two-dimensional, three-dimensional, real-time, analog, digital and/or any other type of imaging. Exemplary embodiments of both control system 204 and display 206 are described in greater detail herein.


Region of interest 210, can be comprised of superficial layer (epidermis/dermis) subcutaneous fat, lobuli, and muscle. Exemplary transducer system 200, is configured to provide cross-sectional two-dimensional imaging of the region 207, displayed as an image 205, with a controlled thermal lesion 209, confined approximately to proximal portion of fat lobuli and lower portion of dermis.


Transducer system 200 can be configured with the ability to controllably produce conformal treatment areas in superficial human tissue within region of interest 210 through precise spatial and temporal control of acoustic energy deposition. In accordance with an exemplary embodiment, control system 204 and transducer probe 202 can be suitably configured for spatial control of the acoustic energy by controlling the manner of distribution of the acoustical energy. For example, spatial control may be realized through selection of the type of one or more transducer configurations insonifying region of interest 210, selection of the placement and location of transducer probe 202 for delivery of acoustical energy relative to region-of-interest 210, e.g., transducer probe 202 configured for scanning over part or whole of region-of-interest 210 to deliver conformal ultrasound therapeutic energy to create a thermal injury and to coagulate the proximal protrusions of fat lobuli, thereby eliminating the fat protrusions into the dermis. Transducer probe 202 may also be configured for control of other environment parameters, e.g., the temperature at the acoustic coupling interface can be controlled. In addition to the spatial control, control system 204 and/or transducer probe 202 can also be configured for temporal control, such as through adjustment and optimization of drive amplitude levels, frequency/waveform selections, and timing sequences and other energy drive characteristics to control the treatment of tissue. The spatial and/or temporal control can also be facilitated through open-loop and closed-loop feedback arrangements, such as through the monitoring of various positional and temporal characteristics. For example, through such spatial and/or temporal control, an exemplary treatment system 200 can enable the regions of thermal injury to possess arbitrary shape and size and allow the tissue to be treated in a controlled manner.


Transducer system 200 may be used to provide a mechanical action of ultrasound to physically break fat cell clusters and stretch the fibrous bonds. This mechanical action will also enhance lymphatic drainage, stimulating the evacuation of fat decay products. That is, the ultrasound may facilitate movement of the muscles and soft tissues within ROI 210, thereby facilitating the loosening of fat deposits and/or the break up of fibrous tissue surrounding fat deposits.


In addition, transducer system 200 can be configured to deliver various therapeutic levels of ultrasound to increase the speed at which fat metabolizes, according to the Arrhenius Law: Y=Ae−B/T, where Y is the yield of metabolic reaction, A and B are constants, and T is the temperature in degrees Kelvin. In one exemplary embodiment, transducer system 200 is configured to provide various therapeutic levels of ultrasound to increase the speed at which fat metabolizes. That is, according to Arrhenius Law, the yield, Y of a metabolic reaction is a function of temperature, T: Y=Ae−B/T, where A and B are constants, and T is the temperature in degrees Kelvin. Thus, ultrasound treatment from transducer system 200, ranging from approximately 750 kHz to 20 MHz, can increase the temperature in a treatment area, thereby increasing the metabolic reaction yield for that treatment area.


As previously described, control systems 104 and 204 may be configured in various manners with various subsystems and subcomponents. With reference to FIGS. 3A and 3B, in accordance with exemplary embodiments, an exemplary control system 300 can be configured for coordination and control of the entire therapeutic treatment process in accordance with the adjustable settings made by a therapeutic treatment system user. For example, control system 300 can suitably comprise power source components 302, sensing and monitoring components 304, cooling and coupling controls 306, and/or processing and control logic components 308. Control system 300 can be configured and optimized in a variety of ways with more or less subsystems and components to implement the therapeutic system for cellulite treatment, and the embodiment in FIGS. 3A and 3B are merely for illustration purposes.


For example, for power sourcing components 302, control system 300 can comprise one or more direct current (DC) power supplies 303 configured to provide electrical energy for entire control system 300, including power required by a transducer electronic amplifier/driver 312. A DC current sense device 305 can also be provided to confirm the level of power going into amplifiers/drivers 312 for safety and monitoring purposes.


Amplifiers/drivers 312 can comprise multi-channel or single channel power amplifiers and/or drivers. In accordance with an exemplary embodiment for transducer array configurations, amplifiers/drivers 312 can also be configured with a beamformer to facilitate array focusing. An exemplary beamformer can be electrically excited by an oscillator/digitally controlled waveform synthesizer 310 with related switching logic.


The power sourcing components can also include various filtering configurations 314. For example, switchable harmonic filters and/or matching may be used at the output of amplifier/driver 312 to increase the drive efficiency and effectiveness. Power detection components 316 may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components 316 may be used to monitor the amount of power going to an exemplary probe system.


Various sensing and monitoring components 304 may also be suitably implemented within control system 300. For example, in accordance with an exemplary embodiment, monitoring, sensing and interface control components 324 may be configured to operate with various motion detection systems 322 implemented within transducer probe 104 to receive and process information such as acoustic or other spatial and temporal information from a region of interest. Sensing and monitoring components can also include various controls, interfacing and switches 309 and/or power detectors 316. Such sensing and monitoring components 304 can facilitate open-loop and/or closed-loop feedback systems within treatment system 100.


For example, In such an open-loop system, a system user can suitably monitor the imaging and/or other spatial or temporal parameters and then adjust or modify same to accomplish a particular treatment objective. Instead of, or in combination with open-loop feedback configurations, an exemplary treatment system can comprise a closed-loop feedback system, wherein images and/or spatial/temporal parameters can be suitably monitored within monitoring component to generate signals.


During operation of exemplary treatment system 100, a lesion configuration of a selected size, shape, orientation is determined. Based on that lesion configuration, one or more spatial parameters are selected, along with suitable temporal parameters, the combination of which yields the desired conformal lesion. Operation of the transducer can then be initiated to provide the conformal lesion or lesions. Open and/or closed-loop feedback systems can also be implemented to monitor the spatial and/or temporal characteristics, and/or other tissue parameter monitoring, to further control the conformal lesions.


Cooling/coupling control systems 306 may be provided to remove waste heat from exemplary probe 104, provide a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from transducer probe 104 to region-of-interest 106. Such cooling/coupling control systems 306 can also be configured to operate in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.


Processing and control logic components 308 can comprise various system processors and digital control logic 307, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays (FPGAs), computer boards, and associated components, including firmware and control software 326, which interfaces to user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software and firmware 326 controls all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches 308 can also be suitably configured to control operation.


An exemplary transducer probe 104 can also be configured in various manners and comprise a number of reusable and/or disposable components and parts in various embodiments to facilitate its operation. For example, transducer probe 104 can be configured within any type of transducer probe housing or arrangement for facilitating the coupling of transducer to a tissue interface, with such housing comprising various shapes, contours and configurations depending on the particular treatment application. For example, in accordance with an exemplary embodiment, transducer probe 104 can be depressed against a tissue interface whereby blood perfusion is partially or wholly cut-off, and tissue flattened in superficial treatment region-of-interest 106. Transducer probe 104 can comprise any type of matching, such as for example, electric matching, which may be electrically switchable; multiplexer circuits and/or aperture/element selection circuits; and/or probe identification devices, to certify probe handle, electric matching, transducer usage history and calibration, such as one or more serial EEPROM (memories). Transducer probe 104 may also comprise cables and connectors; motion mechanisms, motion sensors and encoders; thermal monitoring sensors; and/or user control and status related switches, and indicators such as LEDs. For example, a motion mechanism in probe 104 may be used to controllably create multiple lesions, or sensing of probe motion itself may be used to controllably create multiple lesions and/or stop creation of lesions, e.g. for safety reasons if probe 104 is suddenly jerked or is dropped. In addition, an external motion encoder arm may be used to hold the probe during use, whereby the spatial position and attitude of probe 104 is sent to the control system to help controllably create lesions. Furthermore, other sensing functionality such as profilometers or other imaging modalities may be integrated into the probe in accordance with various exemplary embodiments.


With reference to FIGS. 4A and 4B, in accordance with an exemplary embodiment, a transducer probe 400 can comprise a control interface 402, a transducer 404, coupling components 406, and monitoring/sensing components 408, and/or motion mechanism 410. However, transducer probe 400 can be configured and optimized in a variety of ways with more or less parts and components to provide ultrasound energy for cellulite treatment, and the embodiment in FIGS. 4A and 4B are merely for illustration purposes.


In accordance with an exemplary embodiment of the present invention, transducer probe 400 is configured to deliver energy over varying temporal and/or spatial distributions in order to provide energy effects and initiate responses in a region of interest. These effects can include, for example, thermal, cavitational, hydrodynamic, and resonance induced tissue effects. For example, exemplary transducer probe 400 can be operated under one or more frequency ranges to provide two or more energy effects and initiate one or more responses in the region of interest. In addition, transducer probe 400 can also be configured to deliver planar, defocused and/or focused energy to a region of interest to provide two or more energy effects and to initiate one or more reactions. These responses can include, for example, diathermy, hemostasis, revascularization, angiogenesis, growth of interconnective tissue, tissue reformation, ablation of existing tissue, protein synthesis and/or enhanced cell permeability. These and various other exemplary embodiments for such combined ultrasound treatment, effects and responses are more fully set forth in U.S. patent application Ser. No. 10/950,112, entitled “METHOD AND SYSTEM FOR COMBINED ULTRASOUND TREATMENT,” Filed Sep. 24, 2004 and incorporated herein by reference.


Control interface 402 is configured for interfacing 428 with control system 300 to facilitate control of transducer probe 400. Control interface components 402 can comprise multiplexer/aperture select 424, switchable electric matching networks 426, serial EEPROMs and/or other processing components and matching and probe usage information 430 and interface connectors 432.


Coupling components 406 can comprise various devices to facilitate coupling of transducer probe 400 to a region of interest. For example, coupling components 406 can comprise cooling and acoustic coupling system 420 configured for acoustic coupling of ultrasound energy and signals. Acoustic cooling/coupling system 420 with possible connections such as manifolds may be utilized to couple sound into the region-of-interest, control temperature at the interface and deeper into tissue, provide liquid-filled lens focusing, and/or to remove transducer waste heat. Coupling system 420 may facilitate such coupling through use of various coupling mediums, including air and other gases, water and other fluids, gels, solids, and/or any combination thereof, or any other medium that allows for signals to be transmitted between transducer active elements 412 and a region of interest. In addition to providing a coupling function, in accordance with an exemplary embodiment, coupling system 420 can also be configured for providing temperature control during the treatment application. For example, coupling system 420 can be configured for controlled cooling of an interface surface or region between transducer probe 400 and a region of interest and beyond and beyond and beyond by suitably controlling the temperature of the coupling medium. The suitable temperature for such coupling medium can be achieved in various manners, and utilize various feedback systems, such as thermocouples, thermistors or any other device or system configured for temperature measurement of a coupling medium. Such controlled cooling can be configured to further facilitate spatial and/or thermal energy control of transducer probe 400.


In accordance with an exemplary embodiment, with additional reference to FIG. 11, acoustic coupling and cooling 1140 can be provided to acoustically couple energy and imaging signals from transducer 1104 to and from the region of interest 1102, to provide thermal control at the probe 1100 to region-of-interest interface 1110, and to remove potential waste heat from the transducer probe at region 1144. Temperature monitoring can be provided at the coupling interface via a thermal sensor 1146 to provide a mechanism of temperature measurement 1148 and control via control system 1106 and a thermal control system 1142. Thermal control may consist of passive cooling such as via heat sinks or natural conduction and convection or via active cooling such as with peltier thermoelectric coolers, refrigerants, or fluid-based systems comprised of pump, fluid reservoir, bubble detection, flow sensor, flow channels/tubing 1144 and thermal control 1142.


Monitoring and sensing components 408 can comprise various motion and/or position sensors 416, temperature monitoring sensors 418, user control and feedback switches 414 and other like components for facilitating control by control system 300, e.g., to facilitate spatial and/or temporal control through open-loop and closed-loop feedback arrangements that monitor various spatial and temporal characteristics.


Motion mechanism 410 can comprise manual operation, mechanical arrangements, or some combination thereof. For example, a motion mechanism 422 can be suitably controlled by control system 300, such as through the use of accelerometers, encoders or other position/orientation devices 416 to determine and enable movement and positions of transducer probe 400. Linear, rotational or variable movement can be facilitated, e.g., those depending on the treatment application and tissue contour surface.


Transducer 404 can comprise one or more transducers configured for producing conformal lesions of thermal injury in superficial human tissue within a region of interest through precise spatial and temporal control of acoustic energy deposition. Transducer 404 can also comprise one or more transduction elements and/or lenses 412. The transduction elements can comprise a piezoelectrically active material, such as lead zirconate titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In addition to, or instead of, a piezoelectrically active material, transducer 404 can comprise any other materials configured for generating radiation and/or acoustical energy. Transducer 404 can also comprise one or more matching layers configured along with the transduction element such as coupled to the piezoelectrically active material. Acoustic matching layers and/or damping may be employed as necessary to achieve the desired electroacoustic response.


In accordance with an exemplary embodiment, the thickness of the transduction element of transducer 404 can be configured to be uniform. That is, a transduction element 412 can be configured to have a thickness that is substantially the same throughout. In accordance with another exemplary embodiment, the thickness of a transduction element 412 can also be configured to be variable. For example, transduction element(s) 412 of transducer 404 can be configured to have a first thickness selected to provide a center operating frequency of a lower range, for example from approximately 750 kHz to 5 MHz. Transduction element 404 can also be configured with a second thickness selected to provide a center operating frequency of a higher range, for example from approximately 5 MHz to 20 MHz or more. Transducer 404 can be configured as a single broadband transducer excited with at least two or more frequencies to provide an adequate output for generating a desired response. Transducer 404 can also be configured as two or more individual transducers, wherein each transducer comprises one or more transduction element. The thickness of the transduction elements can be configured to provide center-operating frequencies in a desired treatment range. For example, transducer 404 can comprise a first transducer configured with a first transduction element having a thickness corresponding to a center frequency range of approximately 750 kHz to 5 MHz, and a second transducer configured with a second transduction element having a thickness corresponding to a center frequency of approximately 5 MHz to 20 MHz or more.


Transducer 404 may be composed of one or more individual transducers in any combination of focused, planar, or unfocused single-element, multi-element, or array transducers, including 1-D, 2-D, and annular arrays; linear, curvilinear, sector, or spherical arrays; spherically, cylindrically, and/or electronically focused, defocused, and/or lensed sources. For example, with reference to an exemplary embodiment depicted in FIG. 5, transducer 500 can be configured as an acoustic array to facilitate phase focusing. That is, transducer 500 can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays. By the term “operated,” the electronic apertures of transducer 500 may be manipulated, driven, used, and/or configured to produce and/or deliver an energy beam corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams 508, planar beams 504, and/or focused beams 506, each of which may be used in combination to achieve different physiological effects in a region of interest 510. Transducer 500 may additionally comprise any software and/or other hardware for generating, producing and/or driving a phased aperture array with one or more electronic time delays.


Transducer 500 can also be configured to provide focused treatment to one or more regions of interest using various frequencies. In order to provide focused treatment, transducer 500 can be configured with one or more variable depth devices to facilitate treatment. For example, transducer 500 may be configured with variable depth devices disclosed in U.S. patent application Ser. No. 10/944,500, entitled “System and Method for Variable Depth Ultrasound”, filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and incorporated herein by reference. In addition, transducer 500 can also be configured to treat one or more additional ROI 510 through the enabling of sub-harmonics or pulse-echo imaging, as disclosed in U.S. patent application Ser. No. 10/944,499, entitled “Method and System for Ultrasound Treatment with a Multi-directional Transducer”, filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and also incorporated herein by reference.


Moreover, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and/or defocus the sound field. For example, with reference to exemplary embodiments depicted in FIGS. 6A and 6B, transducer 600 may also be configured with an electronic focusing array 604 in combination with one or more transduction elements 606 to facilitate increased flexibility in treating ROI 610. Array 602 may be configured in a manner similar to transducer 502. That is, array 602 can be configured as an array 604 of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, T1, T2 . . . Tj. By the term “operated,” the electronic apertures of array 604 may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI 610.


Transduction elements 606 may be configured to be concave, convex, and/or planar. For example, in an exemplary embodiment depicted in FIG. 6A, transduction elements 606 are configured to be concave in order to provide focused energy for treatment of ROI 610. Additional embodiments are disclosed in U.S. patent application Ser. No. 10/944,500, entitled “Variable Depth Transducer System and Method”, and again incorporated herein by reference.


In another exemplary embodiment, depicted in FIG. 6B, transduction elements 606 can be configured to be substantially flat in order to provide substantially uniform energy to ROI 610. While FIGS. 6A and 6B depict exemplary embodiments with transduction elements 604 configured as concave and substantially flat, respectively, transduction elements 604 can be configured to be concave, convex, and/or substantially flat. In addition, transduction elements 604 can be configured to be any combination of concave, convex, and/or substantially flat structures. For example, a first transduction element can be configured to be concave, while a second transduction element can be configured to be substantially flat.


With reference to FIGS. 8A and 8B, transducer 800 can be configured as single-element arrays, wherein a single-element 802, e.g., a transduction element of various structures and materials, can be configured with a plurality of masks 804, such masks comprising ceramic, metal or any other material or structure for masking or altering energy distribution from element 802, creating an array of energy distributions 808. Masks 804 can be coupled directly to element 802 or separated by a standoff 806, such as any suitably solid or liquid material.


An exemplary transducer 404 can also be configured as an annular array to provide planar, focused and/or defocused acoustical energy. For example, with reference to FIGS. 10A and 10B, in accordance with an exemplary embodiment, an annular array 1000 can comprise a plurality of rings 1012, 1014, 1016 to N. Rings 1012, 1014, 1016 to N can be mechanically and electrically isolated into a set of individual elements, and can create planar, focused, or defocused waves. For example, such waves can be centered on-axis, such as by methods of adjusting corresponding transmit and/or receive delays, t1, t2, t3 . . . tN. An electronic focus can be suitably moved along various depth positions, and can enable variable strength or beam tightness, while an electronic defocus can have varying amounts of defocusing. In accordance with an exemplary embodiment, a lens and/or convex or concave shaped annular array 1000 can also be provided to aid focusing or defocusing such that any time differential delays can be reduced. Movement of annular array 1000 in one, two or three-dimensions, or along any path, such as through use of probes and/or any conventional robotic arm mechanisms, may be implemented to scan and/or treat a volume or any corresponding space within a region of interest.


Transducer 404 can also be configured in other annular or non-array configurations for imaging/therapy functions. For example, with reference to FIGS. 10C-10F, a transducer can comprise an imaging element 1012 configured with therapy element(s) 1014. Elements 1012 and 1014 can comprise a single-transduction element, e.g., a combined imaging/transducer element, or separate elements, can be electrically isolated 1022 within the same transduction element or between separate imaging and therapy elements, and/or can comprise standoff 1024 or other matching layers, or any combination thereof. For example, with particular reference to FIG. 10F, a transducer can comprise an imaging element 1012 having a surface 1028 configured for focusing, defocusing or planar energy distribution, with therapy elements 1014 including a stepped-configuration lens configured for focusing, defocusing, or planar energy distribution.


In accordance with another aspect of the invention, transducer probe 400 may be configured to provide one, two or three-dimensional treatment applications for focusing acoustic energy to one or more regions of interest. For example, as discussed above, transducer probe 400 can be suitably diced to form a one-dimensional array, e.g., a transducer comprising a single array of sub-transduction elements.


In accordance with another exemplary embodiment, transducer probe 400 may be suitably diced in two-dimensions to form a two-dimensional array. For example, with reference to FIG. 9, an exemplary two-dimensional array 900 can be suitably diced into a plurality of two-dimensional portions 902. Two-dimensional portions 902 can be suitably configured to focus on the treatment region at a certain depth, and thus provide respective slices 904 of the treatment region. As a result, the two-dimensional array 900 can provide a two-dimensional slicing of the image place of a treatment region, thus providing two-dimensional treatment.


In accordance with another exemplary embodiment, transducer probe 400 may be suitably configured to provide three-dimensional treatment. For example, to provide three dimensional treatment of a region of interest, with reference again to FIG. 3, a three-dimensional system can comprise transducer probe 400 configured with an adaptive algorithm, such as, for example, one utilizing three-dimensional graphic software, contained in a control system, such as control system 300. The adaptive algorithm is suitably configured to receive two-dimensional imaging, temperature and/or treatment information relating to the region of interest, process the received information, and then provide corresponding three-dimensional imaging, temperature and/or treatment information.


In accordance with an exemplary embodiment, with reference again to FIG. 9, an exemplary three-dimensional system can comprise a two-dimensional array 900 configured with an adaptive algorithm to suitably receive slices 904, 907 from different image planes of the treatment region, process the received information, and then provide volumetric information 906, e.g., three-dimensional imaging, temperature and/or treatment information. Moreover, after processing the received information with the adaptive algorithm, the two-dimensional array 900 may suitably provide therapeutic heating to the volumetric region 906 as desired.


Alternatively, rather than utilizing an adaptive algorithm, such as three-dimensional software, to provide three-dimensional imaging and/or temperature information, an exemplary three-dimensional system can comprise a single transducer 404 configured within a probe arrangement to operate from various rotational and/or translational positions relative to a target region.


To further illustrate the various structures for transducer 404, with reference to FIG. 7, ultrasound therapy transducer 700 can be configured for a single focus, an array of foci, a locus of foci, a line focus, and/or diffraction patterns. Transducer 700 can also comprise single elements, multiple elements, annular arrays, one-, two-, or three-dimensional arrays, broadband transducers, and/or combinations thereof, with or without lenses, acoustic components, and mechanical and/or electronic focusing. Transducers configured as spherically focused single elements 702, annular arrays 704, annular arrays with damped regions 706, line focused single elements 708, 1-D linear arrays 710, 1-D curvilinear arrays 712 in concave or convex form, with or without elevation focusing, 2-D arrays 714, and 3-D spatial arrangements of transducers may be used to perform therapy and/or imaging and acoustic monitoring functions. For any transducer configuration, focusing and/or defocusing may be in one plane or two planes via mechanical focus 720, convex lens 722, concave lens 724, compound or multiple lenses 726, planar form 728, or stepped form, such as illustrated in FIG. 10F. Any transducer or combination of transducers may be utilized for treatment. For example, an annular transducer may be used with an outer portion dedicated to therapy and the inner disk dedicated to broadband imaging wherein such imaging transducer and therapy transducer have different acoustic lenses and design, such as illustrated in FIG. 10C-10F.


Various shaped treatment lesions can be produced using the various acoustic lenses and designs in FIGS. 10A-10F. For example, mushroom shaped lesions may be produced from a spherically focused source, and/or planar lesions from a flat source. That is, as the application of ablative ultrasound energy continues, this causes thermal expansion to generate a growing lesion. Concave planar sources and arrays can produce a “V-shaped” or ellipsoidal lesion. Electronic arrays, such as a linear array, can produce defocused, planar, or focused acoustic beams that may be employed to form a wide variety of additional lesion shapes at various depths. An array may be employed alone or in conjunction with one or more planar or focused transducers. Such transducers and arrays in combination produce a very wide range of acoustic fields and their associated benefits. A fixed focus and/or variable focus lens or lenses may be used to further increase treatment flexibility. A convex-shaped lens, with acoustic velocity less than that of superficial tissue, may be utilized, such as a liquid-filled lens, gel-filled or solid gel lens, rubber or composite lens, with adequate power handling capacity; or a concave-shaped, low profile, lens may be utilized and composed of any material or composite with velocity greater than that of tissue. While the structure of transducer source and configuration can facilitate a particular shaped lesion as suggested above, such structures are not limited to those particular shapes as the other spatial parameters, as well as the temporal parameters, can facilitate additional shapes within any transducer structure and source.


Through operation of ultrasound system 100, a method for treatment of cellulite can be realized that can facilitate effective and efficient therapy without creating chronic injury to human tissue. For example, a user may first select one or more transducer probe configurations for treating a region of interest. The user may select any probe configuration described herein. Because the treatment region ranges from approximately 0 mm to 3.5 cm, exemplary transducer probes may include, for example, an annular array, a variable depth transducer, a mechanically moveable transducer, a cylindrical-shaped transducer, a linear or flat transducer and the like. As used herein, the term user may include a person, employee, doctor, nurse, and/or technician, utilizing any hardware and/or software of other control systems.


Once one or more transducers are selected, the user may then image a region of interest in order to plan a treatment protocol. By imaging a region of interest, the user may user the same treatment transducer probe and/or one or more additional transducers to image the region of interest at a high resolution. In one embodiment, the transducer may be configured to facilitate high speed imaging over a large region of interest to enable accurate imaging over a large region of interest. In another embodiment, ultrasound imaging may include the use of Doppler flow monitoring and/or color flow monitoring. In addition other means of imaging such as photography and other visual optical methods, MRI, X-Ray, PET, infrared or others can be utilized separately or in combination for imaging and feedback of the superficial tissue and the vascular tissue in the region of interest.


In accordance with another exemplary embodiment, with reference to FIG. 12, an exemplary treatment system 200 can be configured with and/or combined with various auxiliary systems to provide additional functions. For example, an exemplary treatment system 1200 for treating a region of interest 1206 can comprise a control system 1202, a probe 1204, and a display 1208. Treatment system 1200 further comprises an auxiliary imaging modality 1274 and/or auxiliary monitoring modality 1272 may be based upon at least one of photography and other visual optical methods, magnetic resonance imaging (MRI), computed tomography (CT), optical coherence tomography (OCT), electromagnetic, microwave, or radio frequency (RF) methods, positron emission tomography (PET), infrared, ultrasound, acoustic, or any other suitable method of visualization, localization, or monitoring of cellulite within region-of-interest 1206, including imaging/monitoring enhancements. Such imaging/monitoring enhancement for ultrasound imaging via probe 1204 and control system 1202 could comprise M-mode, persistence, filtering, color, Doppler, and harmonic imaging among others; furthermore an ultrasound treatment system 1270, as a primary source of treatment, may be combined with a secondary source of treatment 1276, including radio frequency (RF), intense pulsed light (IPL), laser, infrared laser, microwave, or any other suitable energy source.


Because the location and thickness of the fat lobuli varies from one patient to another (due to genetics, weight, age, etc.), imaging using a transducer can facilitate treatment within a patient, however imaging is not required to treat cellulite.


By planning a treatment protocol, the user may choose one or more spatial and/or temporal characteristics to provide conformal ultrasound energy to a region of interest. For example, the user may select one or more spatial characteristics to control, including, for example, the use one or more transducers, one or more mechanical and/or electronic focusing mechanisms, one or more transduction elements, one or more placement locations of the transducer relative to the region of interest, one or more feedback systems, one or more mechanical arms, one or more orientations of the transducer, one or more temperatures of treatment, one or more coupling mechanisms and/or the like.


In addition, the user may choose one or more temporal characteristics to control in order to facilitate treatment of the region of interest. For example, the user may select and/or vary the treatment time, frequency, power, energy, amplitude and/or the like in order to facilitate temporal control. For more information on selecting and controlling ultrasound spatial and temporal characteristics, see U.S. application Ser. No. 11/163,148, entitled “Method and System for Controlled Thermal Injury,” filed Oct. 6, 2005 and previously incorporated herein by reference.


After planning of a treatment protocol is complete, the treatment protocol can be implemented. That is, a transducer system can be used to deliver ultrasound energy to a treatment region to ablate select tissue in order to facilitate cellulite treatment. By delivering energy, the transducer may be driven at a select frequency, a phased array may be driven with certain temporal and/or spatial distributions, a transducer may be configured with one or more transduction elements to provide focused, defocused and/or planar energy, and/or the transducer may be configured and/or driven in any other ways hereinafter devised.


In one exemplary embodiment, energy is delivered in relatively small ablative areas in order to minimize and/or prevent scar tissue from forming. That is, each ablative area of treatment can range from approximately 100 microns to 55 mm in diameter. In another exemplary embodiment, ultrasound energy is used in a “lawnmower” type fashion to evenly ablate a treatment region to provide a substantially planar surface of lobuli. This “lawnmower”-type ablation in turn, helps to achieve a substantially smooth surface of the epidermis.


In one exemplary embodiment, energy is delivered at a treatment depth of approximately 0 mm to 3.5 cm. The energy may range from 750 kHz to about 10 MHz, with typical applications ranging from 2 MHz to 10 MHz. In order to deliver energy in this treatment range, the transducer can be driven at power levels ranging from 20 W to 200 W. Because treatment time and treatment power are interrelated, these variables may differ from one patient to another and/or from one region of interest to another.


Once the treatment protocol has been implemented, the region of tissue may have one or more reactions to the treatment. For example, in one embodiment, the tissue responds by enhancement of lymphatic drainage, evacuation of fat decay products, creation of a thermal injury and/or coagulation of proximal protrusions of fat lobuli.


Upon treatment, the steps outlined above can be repeated one or more additional times to provide for optimal treatment results. Different ablation sizes and shapes may affect the recovery time and time between treatments. For example, in general, the larger the surface area of the treatment lesion, the faster the recovery. The series of treatments can also enable the user to tailor additional treatments in response to a patient's responses to the ultrasound treatment.


The present invention has been described above with reference to various exemplary embodiments. However, those skilled in the art will recognize that changes and modifications may be made to the exemplary embodiments without departing from the scope of the present invention. For example, the various operational steps, as well as the components for carrying out the operational steps, may be implemented in alternate ways depending upon the particular application or in consideration of any number of cost functions associated with the operation of the system, e.g., various steps may be deleted, modified, or combined with other steps. These and other changes or modifications are intended to be included within the scope of the present invention, as set forth in the following claims.

Claims
  • 1. An ultrasound probe, comprising: a piezoelectric ultrasound therapy element and a cooling system,wherein the piezoelectric ultrasound therapy element and the cooling system are both configured for acoustic coupling to a superficial layer of skin,wherein the piezoelectric ultrasound therapy element is configured for delivering ultrasound energy with a frequency to produce a temperature at a depth under the superficial layer of skin to form one or more thermal lesions to coagulate fat cells in fat lobuli that protrude into a dermis tissue to reduce an appearance of fat,wherein the cooling system is configured to cool the superficial layer of skin.
  • 2. The probe of claim 1, wherein the piezoelectric ultrasound therapy element delivers the ultrasound energy operating at the frequency ranging from 2 MHz to 20 MHz,wherein the piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy to the depth below the superficial layer of skin,wherein the ultrasound energy generates the one or more thermal lesions with a dimension of between 100 microns to 55 mm in a region of interest.
  • 3. The probe of claim 1, wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: Y=A·e−B/T, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.
  • 4. The probe of claim 1, wherein the piezoelectric ultrasound therapy element is configured to operate with a control system comprising a processor, wherein the piezoelectric ultrasound therapy element is configured for electronic communication with the control system.
  • 5. The probe of claim 1, further comprising a plurality of the piezoelectric ultrasound therapy elements configured to form a plurality of thermal lesions along a region of interest at or below the superficial layer of skin.
  • 6. The probe of claim 1, further comprising an imaging device to image the tissue at the depth under the superficial layer of skin and a motion mechanism configured for linear movement of the piezoelectric ultrasound therapy element to form a plurality of thermal lesions along a region of interest at or below the superficial layer of skin.
  • 7. An ultrasound probe, comprising: at least one piezoelectric ultrasound therapy element and a cooling system,the at least one piezoelectric ultrasound therapy element configured for acoustic coupling to a superficial layer of skin,wherein the at least one piezoelectric ultrasound therapy element is configured to deliver energy with a frequency to produce a temperature to coagulate a plurality of fat cells at a fat lobuli at a depth under the superficial layer of skin,wherein the fat lobuli protrude into a dermis under the superficial layer of skin,wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: Y=A·e−B/T, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin,wherein the cooling system is configured to cool the superficial layer of skin.
  • 8. The probe of claim 7, wherein the at least one piezoelectric ultrasound therapy element emits ultrasound energy with the frequency ranging from 2 MHz to 20 MHz,wherein the ultrasound energy is delivered with a treatment power ranging from 20 W to 200 W,wherein the at least one piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy up to 3.5 cm below the superficial layer of skin,wherein the ultrasound energy generates a thermal lesion with a dimension of between 100 microns to 55 mm in a region of interest.
  • 9. The probe of claim 7, wherein the at least one piezoelectric ultrasound therapy element emits ultrasound energy with the frequency ranging from 2 MHz to 20 MHz,wherein the at least one piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy up to 3.5 cm below the superficial layer of skin,wherein the ultrasound energy generates a thermal lesion with a dimension of between 100 microns to 55 mm in a region of interest.
  • 10. The probe of claim 7, wherein the at least one piezoelectric ultrasound therapy element delivers ultrasound energy, wherein the frequency ranges from 750 kHz to 20 MHz,wherein the at least one piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy up to 3.5 cm below the superficial layer of skin.
  • 11. The probe of claim 7, further comprising a control system, wherein the control system comprises a processor and a power supply; andwherein the ultrasound probe is configured with a concave interface.
  • 12. The probe of claim 7, wherein the at least one piezoelectric ultrasound therapy element is configured to deliver unfocused ultrasound energy.
  • 13. The probe of claim 7, wherein the ultrasound energy is delivered for a treatment of cellulite.
  • 14. The probe of claim 7, further comprising an imaging device selected from the group consisting of: ultrasound, MRI, X-ray, PET, and light.
  • 15. An ultrasound probe, comprising: a housing comprising a plurality of piezoelectric ultrasound therapy elements and a cooling system,wherein the plurality of piezoelectric ultrasound therapy elements delivers ultrasound energy to a tissue below a superficial layer of skin at a frequency ranging from 2 MHz to 20 MHz,wherein the tissue comprises a plurality of fat lobuli that protrude into a dermis,wherein the plurality of piezoelectric ultrasound therapy elements is configured for delivery of the ultrasound energy at a temperature to coagulate at least a portion of a plurality of fat lobuli at one or more depths under the superficial layer of skin,wherein the cooling system is configured to cool the superficial layer of skin.
  • 16. The probe of claim 15, wherein the plurality of piezoelectric ultrasound therapy elements is configured to deliver the ultrasound energy at the one or more depths below the superficial layer of skin, wherein the depth is a single, fixed depth up to 3.5 cm below the superficial layer of skin, wherein the ultrasound energy generates a thermal lesion with a dimension of between 100 microns to 55 mm in a region of interest at or below the superficial layer of skin.
  • 17. The probe of claim 15, wherein the plurality of piezoelectric ultrasound therapy elements is configured to operate with a control system that comprises a spatial control and a temporal control, the spatial control and the temporal control controlling the delivery of the ultrasound energy at a temperature to cause coagulation of at least the portion of the plurality of fat lobuli at the one or more depths under the superficial layer of skin, wherein the ultrasound energy is delivered with a treatment power ranging from 20 W to 200 W.
  • 18. The probe of claim 17, further comprising a storage system comprising probe identification and probe usage history, wherein the probe is reusable.
  • 19. The probe of claim 15, wherein the ultrasound energy increases a speed at which fat metabolizes according to Arrhenius Law: Y=A·e−B/T, where Y is a yield of metabolic reaction, A and B are constants, and T is a temperature in degrees Kelvin.
  • 20. The probe of claim 15, wherein the piezoelectric ultrasound therapy element is configured to deliver the ultrasound energy at an energy level for causing at least one of ablating tissue, stretching fibrous bonds, or stimulating evacuation of fat decay products in a region of interest.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/794,717, filed Feb. 19, 2020, now U.S. Pat. No. 10,888,717, which is a continuation of U.S. patent application Ser. No. 16/272,453, filed Feb. 11, 2019, now U.S. Pat. No. 10,603,523, which is a continuation of U.S. patent application Ser. No. 15/996,295, filed Jun. 1, 2018, now U.S. Pat. No. 10,245,450, which is a continuation of U.S. patent application Ser. No. 15/821,281 filed Nov. 22, 2017, now U.S. Pat. No. 10,010,725, which is a continuation of U.S. patent application Ser. No. 15/650,246 filed Jul. 14, 2017, now U.S. Pat. No. 9,827,450, which is a continuation of U.S. patent application Ser. No. 15/374,918 filed Dec. 9, 2016, now U.S. Pat. No. 9,707,412, which is a continuation of U.S. application Ser. No. 15/041,829 filed Feb. 11, 2016, now U.S. Pat. No. 9,522,290, which is a continuation of U.S. application Ser. No. 14/550,720 filed Nov. 21, 2014, now U.S. Pat. No. 9,283,410, which is a continuation of U.S. application Ser. No. 14/164,598 filed Jan. 27, 2014, now U.S. Pat. No. 8,915,854, which is a continuation of U.S. application Ser. No. 13/789,562 filed Mar. 7, 2013, now U.S. Pat. No. 8,636,665, which is a continuation of U.S. application Ser. No. 13/356,405 filed Jan. 23, 2012, now U.S. Pat. No. 8,672,848, which is a continuation of U.S. application Ser. No. 11/163,154 filed on Oct. 6, 2005, now U.S. Pat. No. 8,133,180, which claims the benefit of priority to U.S. Provisional No. 60/616,753, filed on Oct. 6, 2004, each of which are hereby incorporated by reference in their entirety herein. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57.

US Referenced Citations (1216)
Number Name Date Kind
2427348 Bond et al. Sep 1947 A
2792829 Calosi Feb 1952 A
3913386 Saglio Oct 1975 A
3965455 Hurwitz Jun 1976 A
3992925 Perilhou Nov 1976 A
4039312 Patru Aug 1977 A
4059098 Murdock Nov 1977 A
4101795 Fukumoto Jul 1978 A
4151834 Sato et al. May 1979 A
4166967 Benes et al. Sep 1979 A
4211948 Smith et al. Jul 1980 A
4211949 Brisken et al. Jul 1980 A
4213344 Rose Jul 1980 A
4276491 Daniel Jun 1981 A
4315514 Drewes et al. Feb 1982 A
4325381 Glenn Apr 1982 A
4343301 Indech Aug 1982 A
4372296 Fahim Feb 1983 A
4379145 Masuho et al. Apr 1983 A
4381007 Doss Apr 1983 A
4381787 Hottinger May 1983 A
4397314 Vaguine Aug 1983 A
4409839 Taenzer Oct 1983 A
4417170 Benisncasa Nov 1983 A
4431008 Wanner et al. Feb 1984 A
4441486 Pounds Apr 1984 A
4452084 Taenzer Jun 1984 A
4484569 Driller Nov 1984 A
4507582 Glenn Mar 1985 A
4513749 Kino Apr 1985 A
4513750 Heyman et al. Apr 1985 A
4527550 Ruggera et al. Jul 1985 A
4528979 Marchenko Jul 1985 A
4534221 Fife et al. Aug 1985 A
4566459 Umemura et al. Jan 1986 A
4567895 Putzke Feb 1986 A
4586512 Do-Huu May 1986 A
4587971 Stolfi May 1986 A
4601296 Yerushalmi Jul 1986 A
4620546 Aida et al. Nov 1986 A
4637256 Sugiyama et al. Jan 1987 A
4646756 Watmough Mar 1987 A
4663358 Hyon May 1987 A
4668516 Duraffourd et al. May 1987 A
4672591 Breimesser et al. Jun 1987 A
4680499 Umemura et al. Jul 1987 A
4697588 Reichenberger Oct 1987 A
4754760 Fukukita et al. Jul 1988 A
4757820 Itoh Jul 1988 A
4771205 Mequio Sep 1988 A
4801459 Liburdy Jan 1989 A
4803625 Fu et al. Feb 1989 A
4807633 Fry Feb 1989 A
4817615 Fukukita et al. Apr 1989 A
4858613 Fry Aug 1989 A
4860732 Hasegawa et al. Aug 1989 A
4865041 Hassler Sep 1989 A
4865042 Umemura Sep 1989 A
4867169 Machida Sep 1989 A
4874562 Hyon Oct 1989 A
4875487 Seppi Oct 1989 A
4881212 Takeuchi Nov 1989 A
4891043 Zeimer et al. Jan 1990 A
4893624 Lele Jan 1990 A
4896673 Rose Jan 1990 A
4900540 Ryan et al. Feb 1990 A
4901729 Saitoh Feb 1990 A
4917096 Englehart Apr 1990 A
4932414 Coleman et al. Jun 1990 A
4938216 Lele Jul 1990 A
4938217 Lele Jul 1990 A
4947046 Kawabata et al. Aug 1990 A
4951653 Fry Aug 1990 A
4955365 Fry Sep 1990 A
4958626 Nambu Sep 1990 A
4976709 Sand Dec 1990 A
4979501 Valchanov Dec 1990 A
4992989 Watanabe et al. Feb 1991 A
5012797 Liang May 1991 A
5018508 Fry et al. May 1991 A
5030874 Saito et al. Jul 1991 A
5036855 Fry Aug 1991 A
5040537 Katakura Aug 1991 A
5054310 Flynn Oct 1991 A
5054470 Fry Oct 1991 A
5054491 Saito et al. Oct 1991 A
5070879 Herres Dec 1991 A
5088495 Miyagawa Feb 1992 A
5115814 Griffith May 1992 A
5117832 Sanghvi Jun 1992 A
5123418 Saurel Jun 1992 A
5142511 Kanai et al. Aug 1992 A
5143063 Fellner Sep 1992 A
5143074 Dory Sep 1992 A
5149319 Unger Sep 1992 A
5150711 Dory Sep 1992 A
5150714 Green Sep 1992 A
5152294 Mochizuki et al. Oct 1992 A
5156144 Iwasaki Oct 1992 A
5158536 Sekins Oct 1992 A
5159931 Pini Nov 1992 A
5163421 Bernstein Nov 1992 A
5163436 Saitoh et al. Nov 1992 A
5178135 Uchiyama et al. Jan 1993 A
5190518 Takasu Mar 1993 A
5190766 Ishihara Mar 1993 A
5191880 McLeod Mar 1993 A
5205287 Erbel et al. Apr 1993 A
5209720 Unger May 1993 A
5212671 Fujii et al. May 1993 A
5215680 D'Arrigo Jun 1993 A
5224467 Oku Jul 1993 A
5230334 Klopotek Jul 1993 A
5230338 Allen et al. Jul 1993 A
5247924 Suzuki et al. Sep 1993 A
5255681 Ishimura et al. Oct 1993 A
5257970 Dougherty Nov 1993 A
5265614 Hayakawa Nov 1993 A
5267985 Shimada Dec 1993 A
5269297 Weng Dec 1993 A
5282797 Chess Feb 1994 A
5295484 Marcus Mar 1994 A
5295486 Wollschlager et al. Mar 1994 A
5304169 Sand Apr 1994 A
5305756 Entrekin et al. Apr 1994 A
5321520 Inga et al. Jun 1994 A
5323779 Hardy et al. Jun 1994 A
5327895 Hashimoto et al. Jul 1994 A
5329202 Garlick et al. Jul 1994 A
5348016 Unger et al. Sep 1994 A
5358466 Aida Oct 1994 A
5360268 Hayashi Nov 1994 A
5370121 Reichenberger Dec 1994 A
5370122 Kunig Dec 1994 A
5371483 Bhardwaj Dec 1994 A
5375602 Lancee et al. Dec 1994 A
5379773 Hornsby Jan 1995 A
5380280 Peterson Jan 1995 A
5380519 Schneider et al. Jan 1995 A
5383917 Desai et al. Jan 1995 A
5391140 Schaetzle et al. Feb 1995 A
5391197 Burdette et al. Feb 1995 A
5392259 Bolorforosh Feb 1995 A
5396143 Seyed-Bolorforosh et al. Mar 1995 A
5398689 Connor et al. Mar 1995 A
5406503 Williams Apr 1995 A
5413550 Castel May 1995 A
5417216 Tanaka May 1995 A
5423220 Finsterwald et al. Jun 1995 A
5435311 Umemura Jul 1995 A
5438998 Hanafy Aug 1995 A
5443068 Cline Aug 1995 A
5445611 Eppstein et al. Aug 1995 A
5458596 Lax Oct 1995 A
5460179 Okunuki et al. Oct 1995 A
5460595 Hall et al. Oct 1995 A
5419327 Rohwedder Nov 1995 A
5469854 Unger et al. Nov 1995 A
5471488 Fujio Dec 1995 A
5472405 Buchholtz et al. Dec 1995 A
5487388 Rello et al. Jan 1996 A
5492126 Hennige Feb 1996 A
5496256 Bock Mar 1996 A
5501655 Rolt Mar 1996 A
5503152 Oakley et al. Apr 1996 A
5503320 Webster et al. Apr 1996 A
5507790 Weiss Apr 1996 A
5511296 Dias et al. Apr 1996 A
5520188 Hennige May 1996 A
5522869 Burdette Jun 1996 A
5523058 Umemura et al. Jun 1996 A
5524620 Rosenchein Jun 1996 A
5524624 Tepper Jun 1996 A
5524625 Okazaki Jun 1996 A
5526624 Berg Jun 1996 A
5526812 Dumoulin et al. Jun 1996 A
5526814 Cline et al. Jun 1996 A
5526815 Granz Jun 1996 A
5529070 Augustine et al. Jun 1996 A
5540235 Wilson Jul 1996 A
5558092 Unger Sep 1996 A
5560362 Sliwa et al. Oct 1996 A
5573497 Chapelon Nov 1996 A
5575291 Hayakawa Nov 1996 A
5575807 Faller Nov 1996 A
5577502 Darrow et al. Nov 1996 A
5577507 Snyder et al. Nov 1996 A
5577991 Akui et al. Nov 1996 A
5580575 Unger et al. Dec 1996 A
5601526 Chapelon Feb 1997 A
5603323 Pflugrath et al. Feb 1997 A
5605154 Ries Feb 1997 A
5609562 Kaali Mar 1997 A
5615091 Palatnik Mar 1997 A
5618275 Bock Apr 1997 A
5620479 Diederich Apr 1997 A
5622175 Sudol et al. Apr 1997 A
5617858 Taverna et al. May 1997 A
5638819 Manwaring et al. Jun 1997 A
5643179 Fujimoto Jul 1997 A
5644085 Lorraine et al. Jul 1997 A
5647373 Paltieli Jul 1997 A
5655535 Frlemel et al. Aug 1997 A
5655538 Lorraine Aug 1997 A
5657760 Ying Aug 1997 A
5658328 Johnson Aug 1997 A
5660836 Knowlton Aug 1997 A
5662116 Kondo Sep 1997 A
5665053 Jacobs Sep 1997 A
5665141 Vago Sep 1997 A
5671746 Dreschel et al. Sep 1997 A
5673699 Trahey et al. Oct 1997 A
5676692 Sanghvi Oct 1997 A
5685820 Riek et al. Nov 1997 A
5690608 Watanabe Nov 1997 A
5694936 Fujimoto Dec 1997 A
5697897 Buchholtz Dec 1997 A
5701900 Shehada et al. Dec 1997 A
5704361 Seward et al. Jan 1998 A
5706252 Le Verrier et al. Jan 1998 A
5706564 Rhyne Jan 1998 A
5715823 Wood et al. Feb 1998 A
5720287 Chapelon et al. Feb 1998 A
5722411 Suzuki Mar 1998 A
5727554 Kalend et al. Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5740804 Cerofolini Apr 1998 A
5743863 Chapelon Apr 1998 A
5746005 Steinberg May 1998 A
5746762 Bass May 1998 A
5748767 Raab May 1998 A
5749364 Sliwa et al. May 1998 A
5755228 Wilson et al. May 1998 A
5755753 Knowlton May 1998 A
5762066 Law Jun 1998 A
5763886 Schulte Jun 1998 A
5769790 Watkins Jun 1998 A
5779644 Eberle et al. Jul 1998 A
5792058 Lee Aug 1998 A
5795297 Daigle Aug 1998 A
5795311 Wess Aug 1998 A
5810009 Mine et al. Sep 1998 A
5810888 Fenn Sep 1998 A
5814599 Mitragotri et al. Sep 1998 A
5817013 Ginn et al. Oct 1998 A
5817021 Reichenberger Oct 1998 A
5820564 Slayton Oct 1998 A
5823962 Schaetzle Oct 1998 A
5827204 Grandia et al. Oct 1998 A
5840032 Hatfield et al. Nov 1998 A
5844140 Seale Dec 1998 A
5853367 Chalek et al. Dec 1998 A
5866024 de Villeneuve Feb 1999 A
5869751 Bonin Feb 1999 A
5871524 Knowlton Feb 1999 A
5873902 Sanghvi Feb 1999 A
5876341 Wang et al. Mar 1999 A
5879303 Averkiou et al. Mar 1999 A
5882557 Hayakawa Mar 1999 A
5891034 Bucholz Apr 1999 A
5895356 Andrus et al. Apr 1999 A
5899861 Friemel et al. May 1999 A
5904659 Duarte May 1999 A
5919219 Knowlton Jul 1999 A
5923099 Bilir Jul 1999 A
5924989 Polz Jul 1999 A
5928169 Schatzle et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5938606 Bonnefous Aug 1999 A
5938612 Kline-Schoder Aug 1999 A
5948011 Knowlton Sep 1999 A
5957844 Dekel Sep 1999 A
5957882 Nita et al. Sep 1999 A
5957941 Ream Sep 1999 A
5964707 Fenster et al. Oct 1999 A
5967980 Ferre et al. Oct 1999 A
5968034 Fullmer Oct 1999 A
5971949 Levin Oct 1999 A
5977538 Unger et al. Nov 1999 A
5984881 Ishibashi Nov 1999 A
5984882 Rosenchein Nov 1999 A
5990598 Sudol et al. Nov 1999 A
5997471 Gumb et al. Dec 1999 A
5997497 Nita et al. Dec 1999 A
5999843 Anbar Dec 1999 A
6004262 Putz et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6013032 Savord Jan 2000 A
6014473 Hossack et al. Jan 2000 A
6016255 Bolan et al. Jan 2000 A
6019724 Gronningsaeter et al. Feb 2000 A
6022308 Williams Feb 2000 A
6022317 Cruanas et al. Feb 2000 A
6022327 Chang Feb 2000 A
6030374 McDaniel Feb 2000 A
6036646 Barthe Mar 2000 A
6039048 Silberg Mar 2000 A
6039689 Lizzi Mar 2000 A
6042556 Beach Mar 2000 A
6049159 Barthe Apr 2000 A
6050943 Slayton Apr 2000 A
6059727 Fowlkes May 2000 A
6071239 Cribbs Jun 2000 A
6080108 Dunham Jun 2000 A
6083148 Williams Jul 2000 A
6086535 Ishibashi Jul 2000 A
6086580 Morden et al. Jul 2000 A
6090054 Tagishi Jul 2000 A
6093148 Fujimoto Jul 2000 A
6093883 Sanghvi Jul 2000 A
6100626 Frey et al. Aug 2000 A
6101407 Groezinger Aug 2000 A
6106469 Suzuki et al. Aug 2000 A
6113558 Rosenchein Sep 2000 A
6113559 Klopotek Sep 2000 A
6120452 Barthe Sep 2000 A
6123081 Durette Sep 2000 A
6126619 Peterson et al. Oct 2000 A
6135971 Hutchinson Oct 2000 A
6139499 Wilk Oct 2000 A
6159150 Yale et al. Dec 2000 A
6171244 Finger et al. Jan 2001 B1
6176840 Nishimura Jan 2001 B1
6183426 Akisada Feb 2001 B1
6183502 Takeuchi Feb 2001 B1
6183773 Anderson Feb 2001 B1
6190323 Dias Feb 2001 B1
6190336 Duarte Feb 2001 B1
6193658 Wendelken Feb 2001 B1
6198956 Dunne Mar 2001 B1
6210327 Brackett et al. Apr 2001 B1
6213948 Barthe Apr 2001 B1
6216029 Paltieli Apr 2001 B1
6233476 Strommer et al. May 2001 B1
6234990 Rowe et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6246898 Vesely et al. Jun 2001 B1
6251074 Averkiou et al. Jun 2001 B1
6251088 Kaufman et al. Jun 2001 B1
6268405 Yao Jul 2001 B1
6273864 Duarte Aug 2001 B1
6280402 Ishibashi et al. Aug 2001 B1
6287257 Matichuk Sep 2001 B1
6287304 Eggers et al. Sep 2001 B1
6296619 Brisken Oct 2001 B1
6301989 Brown et al. Oct 2001 B1
6307302 Toda Oct 2001 B1
6309355 Cain et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6315741 Martin Nov 2001 B1
6322509 Pan et al. Nov 2001 B1
6322532 D'Sa Nov 2001 B1
6325540 Lounsberry et al. Dec 2001 B1
6325758 Carol et al. Dec 2001 B1
6325769 Klopotek Dec 2001 B1
6325798 Edwards et al. Dec 2001 B1
6338716 Hossack et al. Jan 2002 B1
6350276 Knowlton Feb 2002 B1
6356780 Licato et al. Mar 2002 B1
6361531 Hissong Mar 2002 B1
6370411 Osadchy et al. Apr 2002 B1
6375672 Aksan Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6390982 Bova et al. May 2002 B1
6405090 Knowlton Jun 2002 B1
6409720 Hissong Jun 2002 B1
6413216 Cain et al. Jul 2002 B1
6413253 Koop Jul 2002 B1
6413254 Hissong Jul 2002 B1
6419648 Vitek Jul 2002 B1
6423007 Lizzi et al. Jul 2002 B2
6425865 Salcudean Jul 2002 B1
6425867 Vaezy Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6428477 Mason Aug 2002 B1
6428532 Doukas Aug 2002 B1
6430446 Knowlton Aug 2002 B1
6432057 Mazess et al. Aug 2002 B1
6432067 Martin Aug 2002 B1
6432101 Weber Aug 2002 B1
6436061 Costantino Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6440071 Slayton Aug 2002 B1
6440121 Weber Aug 2002 B1
6443914 Costantino Sep 2002 B1
6447443 Keogh et al. Sep 2002 B1
6450979 Miwa et al. Sep 2002 B1
6451013 Bays et al. Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6461304 Tanaka et al. Oct 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6485420 Bullis Nov 2002 B1
6488626 Lizzi Dec 2002 B1
6491657 Rowe Dec 2002 B2
6500121 Slayton Dec 2002 B1
6500141 Irion Dec 2002 B1
6506171 Vitek et al. Jan 2003 B1
6508774 Acker Jan 2003 B1
6511427 Sliwa, Jr. et al. Jan 2003 B1
6511428 Azuma Jan 2003 B1
6514244 Pope Feb 2003 B2
6517484 Wilk Feb 2003 B1
6524250 Weber Feb 2003 B1
6666835 Martin Mar 2003 B2
6540679 Slayton Apr 2003 B2
6540685 Rhoads et al. Apr 2003 B1
6540700 Fujimoto et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6554771 Buil et al. Apr 2003 B1
6569099 Babaev May 2003 B1
6569108 Sarvazyan et al. May 2003 B2
6572552 Fukukita Jun 2003 B2
6575956 Brisken et al. Jun 2003 B1
6595934 Hissong Jul 2003 B1
6599256 Acker Jul 2003 B1
6605043 Dreschel Aug 2003 B1
6605080 Altshuler et al. Aug 2003 B1
6607498 Eshel Aug 2003 B2
6618620 Freundlich et al. Sep 2003 B1
6623430 Slayton Sep 2003 B1
6626854 Friedman Sep 2003 B2
6626855 Weng Sep 2003 B1
6638226 He et al. Oct 2003 B2
6645145 Dreschel et al. Nov 2003 B1
6645150 Angelsen et al. Nov 2003 B2
6645162 Friedman Nov 2003 B2
6662054 Kreindel Dec 2003 B2
6663627 Francischelli Dec 2003 B2
6665806 Shimizu Dec 2003 B1
6669638 Miller Dec 2003 B1
6685639 Wang et al. Feb 2004 B1
6685640 Fry Feb 2004 B1
6692450 Coleman Feb 2004 B1
6699237 Weber Mar 2004 B2
6716184 Vaezy et al. Apr 2004 B2
6719449 Laughlin Apr 2004 B1
6719694 Weng Apr 2004 B2
6726627 Lizzi et al. Apr 2004 B1
6733449 Krishnamurthy et al. May 2004 B1
6749624 Knowlton Jun 2004 B2
6772490 Toda Aug 2004 B2
6773409 Truckai et al. Aug 2004 B2
6775404 Pagoulatos et al. Aug 2004 B1
6790187 Thompson et al. Sep 2004 B2
6824516 Batten et al. Nov 2004 B2
6825176 White Nov 2004 B2
6835940 Morikawa et al. Dec 2004 B2
6846290 Lizzi et al. Jan 2005 B2
6875176 Mourad et al. Apr 2005 B2
6882884 Mosk et al. Apr 2005 B1
6887239 Elstrom May 2005 B2
6887260 McDaniel May 2005 B1
6889089 Behl May 2005 B2
6896657 Willis May 2005 B2
6902536 Manna Jun 2005 B2
6905466 Saigo Jun 2005 B2
6918907 Kelly Jul 2005 B2
6920883 Bessette Jul 2005 B2
6921371 Wilson Jul 2005 B2
6932771 Whitmore Aug 2005 B2
6932814 Wood Aug 2005 B2
6936044 McDaniel Aug 2005 B2
6936046 Hissong Aug 2005 B2
6945937 Culp et al. Sep 2005 B2
6948843 Laugharn et al. Sep 2005 B2
6953941 Nakano et al. Oct 2005 B2
6958043 Hissong Oct 2005 B2
6971994 Young et al. Dec 2005 B1
6974417 Lockwood Dec 2005 B2
6976492 Ingle Dec 2005 B2
6992305 Maezawa et al. Jan 2006 B2
6997923 Anderson Feb 2006 B2
7006874 Knowlton Feb 2006 B2
7020528 Neev Mar 2006 B2
7022089 Ooba Apr 2006 B2
7058440 Heuscher et al. Jun 2006 B2
7063666 Weng Jun 2006 B2
7070565 Vaezy et al. Jul 2006 B2
7074218 Washington et al. Jul 2006 B2
7094252 Koop Aug 2006 B2
7108663 Talish et al. Sep 2006 B2
7115123 Knowlton Oct 2006 B2
7122029 Koop et al. Oct 2006 B2
7142905 Slayton Nov 2006 B2
7165451 Brooks et al. Jan 2007 B1
7179238 Hissong Feb 2007 B2
7189230 Knowlton Mar 2007 B2
7229411 Slayton Jun 2007 B2
7235592 Muratoglu Jun 2007 B2
7258674 Cribbs Aug 2007 B2
7273459 Desilets Sep 2007 B2
7294125 Phalen et al. Nov 2007 B2
7297117 Trucco Nov 2007 B2
7303555 Makin et al. Dec 2007 B2
7311679 Desilets et al. Dec 2007 B2
7327071 Nishiyama et al. Feb 2008 B2
7331951 Eshel et al. Feb 2008 B2
7332985 Larson et al. Feb 2008 B2
7338434 Haarstad et al. Mar 2008 B1
7347855 Eshel Mar 2008 B2
RE40403 Cho et al. Jun 2008 E
7393325 Barthe Jul 2008 B2
7398116 Edwards Jul 2008 B2
7399279 Abend et al. Jul 2008 B2
7491171 Barthe et al. Feb 2009 B2
7507235 Keogh et al. Mar 2009 B2
7510536 Foley et al. Mar 2009 B2
7517315 Willis Apr 2009 B2
7530356 Slayton May 2009 B2
7530958 Slayton May 2009 B2
7532201 Quistgaard et al. May 2009 B2
7571336 Barthe Aug 2009 B2
7601120 Moilanen et al. Oct 2009 B2
7615015 Coleman Nov 2009 B2
7615016 Barthe Nov 2009 B2
7652411 Crunkilton et al. Jan 2010 B2
7662114 Seip et al. Feb 2010 B2
7674257 Pless et al. Mar 2010 B2
7686763 Vaezy et al. Mar 2010 B2
7713203 Lacoste et al. Mar 2010 B2
7694406 Wildes et al. Apr 2010 B2
7695437 Quistgaard et al. Apr 2010 B2
7727156 Angelsen et al. Jun 2010 B2
7758524 Barthe Jul 2010 B2
7766848 Desilets et al. Aug 2010 B2
7789841 Huckle et al. Sep 2010 B2
7806839 Mast et al. Oct 2010 B2
7815570 Eshel et al. Oct 2010 B2
7819826 Diederich et al. Oct 2010 B2
7828734 Azhari et al. Oct 2010 B2
7824348 Barthe Nov 2010 B2
7833162 Hasegawa et al. Nov 2010 B2
7841984 Cribbs et al. Nov 2010 B2
7846096 Mast et al. Dec 2010 B2
7857773 Desilets et al. Dec 2010 B2
7875023 Eshel et al. Jan 2011 B2
7901359 Mandrusov et al. Mar 2011 B2
7905007 Calisti et al. Mar 2011 B2
7905844 Desilets et al. Mar 2011 B2
7914453 Slayton et al. Mar 2011 B2
7914469 Torbati Mar 2011 B2
7955281 Pedersen et al. Jun 2011 B2
7967764 Lidgren et al. Jun 2011 B2
7967839 Flock et al. Jun 2011 B2
7955262 Rosenberg Jul 2011 B2
7993289 Quistgaard et al. Aug 2011 B2
8057465 Sliwa, Jr. et al. Sep 2011 B2
8057389 Barthe et al. Nov 2011 B2
8066641 Barthe et al. Nov 2011 B2
8123707 Huckle et al. Feb 2012 B2
8128618 Gliklich et al. Mar 2012 B2
8133180 Slayton et al. Mar 2012 B2
8133191 Rosenberg et al. Mar 2012 B2
8142200 Crunkilton et al. Mar 2012 B2
8152904 Slobodzian et al. Apr 2012 B2
8162858 Manna et al. Apr 2012 B2
8166332 Barthe et al. Apr 2012 B2
8182428 Angelsen et al. May 2012 B2
8197409 Foley et al. Jun 2012 B2
8206299 Foley et al. Jun 2012 B2
8208346 Crunkilton Jun 2012 B2
8211017 Foley et al. Jul 2012 B2
8262591 Pedersen et al. Sep 2012 B2
8262650 Zanelli et al. Sep 2012 B2
8264126 Toda et al. Sep 2012 B2
8273037 Kreindel et al. Sep 2012 B2
8282554 Makin et al. Oct 2012 B2
8292835 Cimino Oct 2012 B1
8298163 Cimino Oct 2012 B1
8333700 Barthe et al. Dec 2012 B1
8334637 Crunkilton et al. Dec 2012 B2
8337407 Quistgaard et al. Dec 2012 B2
8343051 Desilets et al. Jan 2013 B2
8454540 Eshel et al. Jan 2013 B2
8366622 Slayton et al. Feb 2013 B2
8398549 Palmeri et al. Mar 2013 B2
8409097 Slayton et al. Apr 2013 B2
8425435 Wing et al. Apr 2013 B2
8388535 Weng et al. May 2013 B2
8444562 Barthe et al. May 2013 B2
8460193 Barthe et al. Jun 2013 B2
8480585 Slayton et al. Jul 2013 B2
8486001 Weyant Jul 2013 B2
8506486 Slayton et al. Aug 2013 B2
8512250 Quistgaard et al. Aug 2013 B2
8523775 Barthe et al. Sep 2013 B2
8523849 Liu et al. Sep 2013 B2
8535228 Slayton et al. Sep 2013 B2
8570837 Toda et al. Oct 2013 B2
8573392 Bennett et al. Nov 2013 B2
8583211 Salomir et al. Nov 2013 B2
8585618 Hunziker et al. Nov 2013 B2
8604672 Toda et al. Dec 2013 B2
8622937 Weng et al. Jan 2014 B2
8636665 Slayton et al. Jan 2014 B2
8641622 Barthe et al. Feb 2014 B2
8663112 Slayton et al. Mar 2014 B2
8672848 Slayton et al. Mar 2014 B2
8690778 Slayton et al. Apr 2014 B2
8690779 Slayton et al. Apr 2014 B2
8690780 Slayton et al. Apr 2014 B2
8708935 Barthe et al. Apr 2014 B2
8715186 Slayton et al. May 2014 B2
8726781 Eckhoff et al. May 2014 B2
8728071 Lischinsky et al. May 2014 B2
8753295 Thierman Jun 2014 B2
8758253 Sano et al. Jun 2014 B2
8836203 Nobles et al. Sep 2014 B2
8857438 Barthe et al. Oct 2014 B2
8858471 Barthe et al. Oct 2014 B2
8915853 Barthe et al. Dec 2014 B2
8915854 Slayton et al. Dec 2014 B2
8915870 Barthe et al. Dec 2014 B2
8920320 Stecco et al. Dec 2014 B2
8920324 Slayton et al. Dec 2014 B2
8926533 Bockenstedt et al. Jan 2015 B2
8932224 Barthe et al. Jan 2015 B2
8932238 Wing et al. Jan 2015 B2
8968205 Zeng et al. Mar 2015 B2
9011336 Slayton et al. Apr 2015 B2
9039617 Slayton et al. May 2015 B2
9039619 Barthe et al. May 2015 B2
9050116 Homer Jun 2015 B2
9095697 Barthe et al. Aug 2015 B2
9107798 Azhari et al. Aug 2015 B2
9114247 Barthe et al. Aug 2015 B2
9180314 Desilets et al. Nov 2015 B2
9216276 Slayton et al. Dec 2015 B2
9220915 Liu et al. Dec 2015 B2
9272162 Slayton et al. Mar 2016 B2
9283409 Slayton et al. Mar 2016 B2
9283410 Slayton et al. Mar 2016 B2
9295607 Rosenberg Mar 2016 B2
9308390 Youngquist Apr 2016 B2
9308391 Liu et al. Apr 2016 B2
9314650 Rosenberg et al. Apr 2016 B2
9320537 Slayton et al. Apr 2016 B2
9345910 Slayton et al. May 2016 B2
9421029 Barthe et al. Aug 2016 B2
9427600 Barthe et al. Aug 2016 B2
9427601 Barthe et al. Aug 2016 B2
9433803 Lin et al. Sep 2016 B2
9440093 Homer Sep 2016 B2
9440096 Barthe et al. Sep 2016 B2
9492645 Zhou et al. Nov 2016 B2
9492686 Da Silva Nov 2016 B2
9498651 Sapozhnikov et al. Nov 2016 B2
9510802 Barthe et al. Dec 2016 B2
9522290 Slayton et al. Dec 2016 B2
9532832 Ron Edoute et al. Jan 2017 B2
9533174 Barthe et al. Jan 2017 B2
9533175 Slayton et al. Jan 2017 B2
9545529 Britva et al. Jan 2017 B2
9566454 Barthe et al. Feb 2017 B2
9623267 Ulric et al. Apr 2017 B2
9694211 Barthe et al. Jul 2017 B2
9694212 Barthe et al. Jul 2017 B2
9700340 Barthe et al. Jul 2017 B2
9707412 Slayton et al. Jul 2017 B2
9710607 Ramdas et al. Jul 2017 B2
9713731 Slayton et al. Jul 2017 B2
9802063 Barthe et al. Oct 2017 B2
9827449 Barthe et al. Nov 2017 B2
9827450 Slayton et al. Nov 2017 B2
9833639 Slayton et al. Dec 2017 B2
9833640 Barthe et al. Dec 2017 B2
9895560 Barthe et al. Feb 2018 B2
9907535 Barthe et al. Mar 2018 B2
9919167 Domankevitz Mar 2018 B2
9974982 Slayton et al. May 2018 B2
9993664 Aviad et al. Jun 2018 B2
10010721 Slayton et al. Jul 2018 B2
10010724 Barthe et al. Jul 2018 B2
10010725 Slayton et al. Jul 2018 B2
10010726 Barthe et al. Jul 2018 B2
10016626 Zovrin et al. Jul 2018 B2
10046181 Barthe et al. Aug 2018 B2
10046182 Barthe et al. Aug 2018 B2
10070883 Barthe et al. Sep 2018 B2
10183183 Burdette Jan 2019 B2
10226645 Barthe Mar 2019 B2
10238894 Slayton et al. Mar 2019 B2
10245450 Slayton et al. Apr 2019 B2
10252086 Barthe et al. Apr 2019 B2
10265550 Barthe et al. Apr 2019 B2
10272272 Lee et al. Apr 2019 B2
10300308 Seip et al. May 2019 B2
10328289 Barthe et al. Jun 2019 B2
10406383 Luebcke Sep 2019 B2
10420960 Emery Sep 2019 B2
10420961 Lacoste Sep 2019 B2
10485573 Clark, III et al. Nov 2019 B2
10492862 Domankevitz Dec 2019 B2
10525288 Slayton et al. Jan 2020 B2
10532230 Barthe et al. Jan 2020 B2
10537304 Barthe et al. Jan 2020 B2
10556123 Altshuler et al. Feb 2020 B2
10583287 Schwarz Mar 2020 B2
10603519 Slayton et al. Mar 2020 B2
10603523 Slayton et al. Mar 2020 B2
10610705 Barthe et al. Apr 2020 B2
10610706 Barthe et al. Apr 2020 B2
10639006 Choi et al. May 2020 B2
10639504 Kim May 2020 B2
10751246 Kaila Aug 2020 B2
10772646 Lu et al. Sep 2020 B2
10780298 Cain et al. Sep 2020 B2
10888716 Slayton et al. Jan 2021 B2
10888717 Slayton et al. Jan 2021 B2
10888718 Barthe et al. Jan 2021 B2
20010009997 Pope Jul 2001 A1
20010009999 Kaufman et al. Jul 2001 A1
20010014780 Martin Aug 2001 A1
20010014819 Ingle Aug 2001 A1
20010031922 Weng Oct 2001 A1
20010039380 Larson et al. Nov 2001 A1
20010041880 Brisken Nov 2001 A1
20020000763 Jones Jan 2002 A1
20020002345 Marlinghaus Jan 2002 A1
20020040199 Klopotek Apr 2002 A1
20020040442 Ishidera Apr 2002 A1
20020055702 Atala May 2002 A1
20020062077 Emmenegger May 2002 A1
20020062142 Knowlton May 2002 A1
20020072691 Thompson et al. Jun 2002 A1
20020082528 Friedman Jun 2002 A1
20020082529 Suorsa et al. Jun 2002 A1
20020082589 Friedman Jun 2002 A1
20020087080 Slayton Jul 2002 A1
20020095143 Key Jul 2002 A1
20020099094 Anderson Jul 2002 A1
20020111569 Rosenschien et al. Aug 2002 A1
20020115917 Honda et al. Aug 2002 A1
20020128639 Pless et al. Aug 2002 A1
20020128648 Weber Sep 2002 A1
20020143252 Dunne et al. Oct 2002 A1
20020156400 Babaev Oct 2002 A1
20020161357 Anderson Oct 2002 A1
20020165529 Danek Nov 2002 A1
20020168049 Schriever Nov 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020169442 Neev Nov 2002 A1
20020173721 Grunwald et al. Nov 2002 A1
20020193784 McHale et al. Dec 2002 A1
20020193831 Smith Dec 2002 A1
20030009153 Brisken et al. Jan 2003 A1
20030014039 Barzell et al. Jan 2003 A1
20030018255 Martin Jan 2003 A1
20030018270 Makin et al. Jan 2003 A1
20030023283 McDaniel Jan 2003 A1
20030028111 Vaezy et al. Feb 2003 A1
20030028113 Gilbert et al. Feb 2003 A1
20030032900 Ella Feb 2003 A1
20030036706 Slayton et al. Feb 2003 A1
20030040739 Koop Feb 2003 A1
20030050678 Sierra Mar 2003 A1
20030055308 Friemel et al. Mar 2003 A1
20030055417 Truckai et al. Mar 2003 A1
20030060736 Martin et al. Mar 2003 A1
20030065313 Koop Apr 2003 A1
20030066708 Allison et al. Apr 2003 A1
20030073907 Taylor Apr 2003 A1
20030074023 Kaplan Apr 2003 A1
20030083536 Eshel May 2003 A1
20030092988 Makin May 2003 A1
20030097071 Halmann et al. May 2003 A1
20030099383 Lefebvre May 2003 A1
20030125629 Ustuner Jul 2003 A1
20030135135 Miwa et al. Jul 2003 A1
20030139790 Ingle et al. Jul 2003 A1
20030149366 Stringer et al. Aug 2003 A1
20030153961 Babaev Aug 2003 A1
20030171678 Batten et al. Sep 2003 A1
20030171701 Babaev Sep 2003 A1
20030176790 Slayton Sep 2003 A1
20030191396 Sanghvi Oct 2003 A1
20030199794 Sakurai et al. Oct 2003 A1
20030200481 Stanley Oct 2003 A1
20030212129 Liu et al. Nov 2003 A1
20030212351 Hissong Nov 2003 A1
20030212393 Knowlton Nov 2003 A1
20030216648 Lizzi et al. Nov 2003 A1
20030216795 Harth Nov 2003 A1
20030220536 Hissong Nov 2003 A1
20030220585 Hissong Nov 2003 A1
20030229331 Brisken et al. Dec 2003 A1
20030233085 Giammarusti Dec 2003 A1
20030236487 Knowlton Dec 2003 A1
20040000316 Knowlton Jan 2004 A1
20040001809 Brisken Jan 2004 A1
20040002658 Marian, Jr. Jan 2004 A1
20040002705 Knowlton Jan 2004 A1
20040010222 Nunomura et al. Jan 2004 A1
20040015079 Berger et al. Jan 2004 A1
20040015106 Coleman Jan 2004 A1
20040030227 Littrup Feb 2004 A1
20040030268 Weng et al. Feb 2004 A1
20040039312 Hillstead Feb 2004 A1
20040039418 Elstrom Feb 2004 A1
20040041563 Lewin et al. Mar 2004 A1
20040041880 Ikeda et al. Mar 2004 A1
20040042168 Yang et al. Mar 2004 A1
20040044375 Diederich et al. Mar 2004 A1
20040049134 Tosaya et al. Mar 2004 A1
20040049734 Tosaya et al. Mar 2004 A1
20040059266 Fry Mar 2004 A1
20040068186 Ishida et al. Apr 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040073113 Salgo Apr 2004 A1
20040073115 Horzewski et al. Apr 2004 A1
20040073116 Smith Apr 2004 A1
20040073204 Ryan et al. Apr 2004 A1
20040077977 Ella et al. Apr 2004 A1
20040082857 Schonenberger Apr 2004 A1
20040082859 Schaer Apr 2004 A1
20040102697 Evron May 2004 A1
20040105559 Aylward et al. Jun 2004 A1
20040106867 Eshel et al. Jun 2004 A1
20040122323 Vortman et al. Jun 2004 A1
20040122493 Ishibashi et al. Jun 2004 A1
20040143297 Ramsey Jul 2004 A1
20040152982 Hwang et al. Aug 2004 A1
20040158150 Rabiner et al. Aug 2004 A1
20040186535 Knowlton Sep 2004 A1
20040189155 Funakubo Sep 2004 A1
20040206365 Knowlton Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040217675 Desilets Nov 2004 A1
20040249318 Tanaka Dec 2004 A1
20040254620 Lacoste Dec 2004 A1
20040267252 Washington et al. Dec 2004 A1
20050007879 Nishida Jan 2005 A1
20050033201 Takahashi Feb 2005 A1
20050033316 Kertz Feb 2005 A1
20050038340 Vaezy et al. Feb 2005 A1
20050055018 Kreindel Mar 2005 A1
20050055073 Weber Mar 2005 A1
20050061834 Garcia et al. Mar 2005 A1
20050070961 Maki Mar 2005 A1
20050074407 Smith Apr 2005 A1
20050080469 Larson Apr 2005 A1
20050085731 Miller et al. Apr 2005 A1
20050091770 Mourad et al. May 2005 A1
20050096542 Weng et al. May 2005 A1
20050104690 Larson et al. May 2005 A1
20050113689 Gritzky May 2005 A1
20050131302 Poland Jun 2005 A1
20050137656 Malak Jun 2005 A1
20050143677 Young et al. Jun 2005 A1
20050154313 Desilets Jul 2005 A1
20050154314 Quistgaard Jul 2005 A1
20050154332 Zanelli Jul 2005 A1
20050154431 Quistgaard Jul 2005 A1
20050187495 Quistgaard Aug 2005 A1
20050191252 Mitsui Sep 2005 A1
20050193451 Quistgaard Sep 2005 A1
20050193820 Sheljaskow et al. Sep 2005 A1
20050197681 Barolet et al. Sep 2005 A1
20050228281 Nefos Oct 2005 A1
20050240127 Seip et al. Oct 2005 A1
20050240170 Zhang et al. Oct 2005 A1
20050251120 Anderson et al. Nov 2005 A1
20050251125 Pless et al. Nov 2005 A1
20050256406 Barthe Nov 2005 A1
20050261584 Eshel Nov 2005 A1
20050261585 Makin et al. Nov 2005 A1
20050267454 Hissong Dec 2005 A1
20050288748 Li et al. Dec 2005 A1
20060004306 Altshuler Jan 2006 A1
20060020260 Dover et al. Jan 2006 A1
20060025756 Francischelli Feb 2006 A1
20060042201 Curry Mar 2006 A1
20060058664 Barthe Mar 2006 A1
20060058671 Vitek et al. Mar 2006 A1
20060058707 Barthe Mar 2006 A1
20060058712 Altshuler et al. Mar 2006 A1
20060074309 Bonnefous Apr 2006 A1
20060074313 Slayton et al. Apr 2006 A1
20060074314 Slayton Apr 2006 A1
20060074355 Slayton Apr 2006 A1
20060079816 Barthe Apr 2006 A1
20060079868 Makin Apr 2006 A1
20060084891 Barthe Apr 2006 A1
20060089632 Barthe Apr 2006 A1
20060089688 Panescu Apr 2006 A1
20060094988 Tosaya May 2006 A1
20060106325 Perrier May 2006 A1
20060111744 Makin May 2006 A1
20060116583 Ogasawara et al. Jun 2006 A1
20060116671 Slayton Jun 2006 A1
20060122508 Slayton Jun 2006 A1
20060122509 Desilets Jun 2006 A1
20060161062 Arditi et al. Jul 2006 A1
20060184069 Vaitekunas Aug 2006 A1
20060184071 Klopotek Aug 2006 A1
20060189972 Grossman Aug 2006 A1
20060206105 Chopra Sep 2006 A1
20060224090 Ostrovsky et al. Oct 2006 A1
20060229514 Wiener Oct 2006 A1
20060238068 May et al. Oct 2006 A1
20060241440 Eshel Oct 2006 A1
20060241442 Barthe Oct 2006 A1
20060241470 Novak et al. Oct 2006 A1
20060241576 Diederich et al. Oct 2006 A1
20060250046 Koizumi et al. Nov 2006 A1
20060282691 Barthe Dec 2006 A1
20060291710 Wang et al. Dec 2006 A1
20070016039 Vortman et al. Jan 2007 A1
20070032784 Gilklich et al. Feb 2007 A1
20070035201 Desilets Feb 2007 A1
20070055154 Torbati Mar 2007 A1
20070055155 Owen et al. Mar 2007 A1
20070055156 Desilets et al. Mar 2007 A1
20070065420 Johnson Mar 2007 A1
20070083120 Cain et al. Apr 2007 A1
20070087060 Dietrich Apr 2007 A1
20070088245 Babaev et al. Apr 2007 A1
20070088346 Mirizzi et al. Apr 2007 A1
20070161902 Dan Jul 2007 A1
20070166357 Shaffer et al. Jul 2007 A1
20070167709 Slayton Jul 2007 A1
20070208253 Slayton Sep 2007 A1
20070219448 Seip et al. Sep 2007 A1
20070219604 Yaroslavsky et al. Sep 2007 A1
20070219605 Yaroslavsky et al. Sep 2007 A1
20070238994 Stecco et al. Oct 2007 A1
20070239075 Rosenberg Oct 2007 A1
20070239077 Azhari et al. Oct 2007 A1
20070239079 Manstein et al. Oct 2007 A1
20070239142 Altshuler Oct 2007 A1
20080015435 Cribbs et al. Jan 2008 A1
20080027328 Klopotek Jan 2008 A1
20080033458 McLean et al. Feb 2008 A1
20080039724 Seip et al. Feb 2008 A1
20080071255 Barthe Mar 2008 A1
20080086054 Slayton Apr 2008 A1
20080086056 Chang et al. Apr 2008 A1
20080097214 Meyers et al. Apr 2008 A1
20080097253 Pedersen et al. Apr 2008 A1
20080114251 Weymer et al. May 2008 A1
20080139943 Deng et al. Jun 2008 A1
20080139974 Da Silva Jun 2008 A1
20080146970 Litman et al. Jun 2008 A1
20080167556 Thompson Jul 2008 A1
20080183077 Moreau-Gobard et al. Jul 2008 A1
20080183110 Davenport et al. Jul 2008 A1
20080188745 Chen et al. Aug 2008 A1
20080194964 Randall et al. Aug 2008 A1
20080195000 Spooner et al. Aug 2008 A1
20080200810 Buchalter Aug 2008 A1
20080200813 Quistgaard Aug 2008 A1
20080214966 Slayton Sep 2008 A1
20080214988 Altshuler et al. Sep 2008 A1
20080221491 Slayton Sep 2008 A1
20080223379 Stuker et al. Sep 2008 A1
20080242991 Moon et al. Oct 2008 A1
20080243035 Crunkilton Oct 2008 A1
20080269608 Anderson et al. Oct 2008 A1
20080275342 Barthe Nov 2008 A1
20080281206 Bartlett et al. Nov 2008 A1
20080281236 Eshel et al. Nov 2008 A1
20080281237 Slayton Nov 2008 A1
20080281255 Slayton Nov 2008 A1
20080294072 Crutchfield, III Nov 2008 A1
20080294073 Barthe Nov 2008 A1
20080319356 Cain Dec 2008 A1
20090005680 Jones et al. Jan 2009 A1
20090012394 Hobelsberger et al. Jan 2009 A1
20090043198 Milner et al. Feb 2009 A1
20090043293 Pankratov et al. Feb 2009 A1
20090048514 Azhari et al. Feb 2009 A1
20090069677 Chen et al. Mar 2009 A1
20090093737 Chomas et al. Apr 2009 A1
20090156969 Santangelo Jun 2009 A1
20090163807 Sliwa Jun 2009 A1
20090171252 Bockenstedt et al. Jul 2009 A1
20090171266 Harris Jul 2009 A1
20090177122 Peterson Jul 2009 A1
20090177123 Peterson Jul 2009 A1
20090182231 Barthe et al. Jul 2009 A1
20090198157 Babaev et al. Aug 2009 A1
20090216159 Slayton et al. Aug 2009 A1
20090226424 Hsu Sep 2009 A1
20090227910 Pedersen et al. Sep 2009 A1
20090230823 Kushculey et al. Sep 2009 A1
20090253988 Slayton et al. Oct 2009 A1
20090281463 Chapelon et al. Nov 2009 A1
20090312693 Thapliyal et al. Dec 2009 A1
20090318909 Debenedictis et al. Dec 2009 A1
20090326420 Moonen et al. Dec 2009 A1
20100011236 Barthe et al. Jan 2010 A1
20100022919 Peterson Jan 2010 A1
20100022921 Seip et al. Jan 2010 A1
20100022922 Barthe et al. Jan 2010 A1
20100030076 Vortman et al. Feb 2010 A1
20100042020 Ben-Ezra Feb 2010 A1
20100049178 Deem et al. Feb 2010 A1
20100056925 Zhang et al. Mar 2010 A1
20100100014 Eshel et al. Apr 2010 A1
20100113983 Heckerman et al. May 2010 A1
20100130891 Taggart et al. May 2010 A1
20100160782 Slayton et al. Jun 2010 A1
20100160837 Hunziker et al. Jun 2010 A1
20100168576 Poland et al. Jul 2010 A1
20100191120 Kraus et al. Jul 2010 A1
20100241035 Barthe et al. Sep 2010 A1
20100249602 Buckley et al. Sep 2010 A1
20100249669 Ulric et al. Sep 2010 A1
20100256489 Pedersen et al. Oct 2010 A1
20100274161 Azhari et al. Oct 2010 A1
20100280420 Barthe et al. Nov 2010 A1
20100286518 Lee et al. Nov 2010 A1
20100312150 Douglas et al. Dec 2010 A1
20110040171 Foley et al. Feb 2011 A1
20110040190 Jahnke et al. Feb 2011 A1
20110040213 Dietz et al. Feb 2011 A1
20110040214 Foley et al. Feb 2011 A1
20110066084 Desilets et al. Mar 2011 A1
20110072970 Slobodzian et al. Mar 2011 A1
20110077514 Ulric et al. Mar 2011 A1
20110079083 Yoo et al. Apr 2011 A1
20110087099 Eshel et al. Apr 2011 A1
20110087255 McCormack et al. Apr 2011 A1
20110112405 Barthe et al. May 2011 A1
20110144490 Davis et al. Jun 2011 A1
20110178444 Slayton et al. Jul 2011 A1
20110178541 Azhari Jul 2011 A1
20110190745 Uebelhoer et al. Aug 2011 A1
20110201976 Sanghvi et al. Aug 2011 A1
20110251524 Azhari et al. Oct 2011 A1
20110251527 Kushculey et al. Oct 2011 A1
20110270137 Goren et al. Nov 2011 A1
20110319793 Henrik et al. Dec 2011 A1
20110319794 Gertner Dec 2011 A1
20120004549 Barthe et al. Jan 2012 A1
20120016239 Barthe et al. Jan 2012 A1
20120029353 Slayton et al. Feb 2012 A1
20120035473 Sanghvi et al. Feb 2012 A1
20120035475 Barthe et al. Feb 2012 A1
20120035476 Barthe et al. Feb 2012 A1
20120046547 Barthe et al. Feb 2012 A1
20120053458 Barthe et al. Mar 2012 A1
20120059288 Barthe et al. Mar 2012 A1
20120111339 Barthe et al. May 2012 A1
20120123304 Rybyanets et al. May 2012 A1
20120136280 Rosenberg et al. May 2012 A1
20120136282 Rosenberg et al. May 2012 A1
20120143056 Slayton et al. Jun 2012 A1
20120143100 Jeong et al. Jun 2012 A1
20120165668 Slayton et al. Jun 2012 A1
20120165848 Slayton et al. Jun 2012 A1
20120191019 Desilets et al. Jul 2012 A1
20120191020 Vitek et al. Jul 2012 A1
20120197120 Makin et al. Aug 2012 A1
20120197121 Slayton et al. Aug 2012 A1
20120209150 Zeng et al. Aug 2012 A1
20120215105 Slayton et al. Aug 2012 A1
20120271202 Wisdom Oct 2012 A1
20120271294 Barthe et al. Oct 2012 A1
20120277639 Pollock et al. Nov 2012 A1
20120296240 Azhari et al. Nov 2012 A1
20120302883 Kong et al. Nov 2012 A1
20120316426 Foley et al. Dec 2012 A1
20120330197 Makin et al. Dec 2012 A1
20120330222 Makin et al. Dec 2012 A1
20120330223 Makin et al. Dec 2012 A1
20120330283 Hyde et al. Dec 2012 A1
20120330284 Hyde et al. Dec 2012 A1
20130012755 Slayton Jan 2013 A1
20130012816 Slayton et al. Jan 2013 A1
20130012838 Jaeger et al. Jan 2013 A1
20130012842 Barthe Jan 2013 A1
20130018285 Park et al. Jan 2013 A1
20130018286 Slayton et al. Jan 2013 A1
20130046209 Slayton et al. Feb 2013 A1
20130051178 Rybyanets Feb 2013 A1
20130060170 Lee et al. Mar 2013 A1
20130066208 Barthe et al. Mar 2013 A1
20130066237 Smotrich et al. Mar 2013 A1
20130072826 Slayton et al. Mar 2013 A1
20130073001 Campbell Mar 2013 A1
20130096471 Slayton et al. Apr 2013 A1
20130096596 Schafer Apr 2013 A1
20130190659 Slayton et al. Jul 2013 A1
20130211293 Auboiroux et al. Aug 2013 A1
20130225994 Hsu et al. Aug 2013 A1
20130268032 Neev Oct 2013 A1
20130274603 Barthe et al. Oct 2013 A1
20130278111 Sammoura Oct 2013 A1
20130281853 Slayton et al. Oct 2013 A1
20130281891 Slayton et al. Oct 2013 A1
20130296697 Slayton et al. Nov 2013 A1
20130296700 Slayton et al. Nov 2013 A1
20130296743 Lee et al. Nov 2013 A1
20130303904 Barthe et al. Nov 2013 A1
20130303905 Barthe et al. Nov 2013 A1
20130310714 Eshel et al. Nov 2013 A1
20130310863 Makin et al. Nov 2013 A1
20130345562 Barthe et al. Dec 2013 A1
20140024974 Slayton et al. Jan 2014 A1
20140050054 Toda et al. Feb 2014 A1
20140081300 Melodelima et al. Mar 2014 A1
20140082907 Barthe et al. Mar 2014 A1
20140117814 Toda et al. May 2014 A1
20140142430 Slayton et al. May 2014 A1
20140148834 Barthe et al. May 2014 A1
20140155747 Bennett Jun 2014 A1
20140180174 Slayton et al. Jun 2014 A1
20140187944 Slayton et al. Jul 2014 A1
20140188015 Slayton et al. Jul 2014 A1
20140188145 Slayton et al. Jul 2014 A1
20140194723 Herzog et al. Jul 2014 A1
20140208856 Schmid Jul 2014 A1
20140221823 Keogh et al. Aug 2014 A1
20140236049 Barthe et al. Aug 2014 A1
20140236061 Lee et al. Aug 2014 A1
20140243713 Slayton et al. Aug 2014 A1
20140257145 Emery Sep 2014 A1
20140276055 Barthe et al. Sep 2014 A1
20150000674 Barthe et al. Jan 2015 A1
20150025420 Slayton et al. Jan 2015 A1
20150064165 Perry et al. Mar 2015 A1
20150080723 Barthe et al. Mar 2015 A1
20150080771 Barthe et al. Mar 2015 A1
20150080874 Slayton et al. Mar 2015 A1
20150088182 Slayton et al. Mar 2015 A1
20150141734 Chapelon et al. May 2015 A1
20150164734 Slayton et al. Jun 2015 A1
20150165238 Slayton et al. Jun 2015 A1
20150165243 Slayton et al. Jun 2015 A1
20150174388 Slayton Jun 2015 A1
20150202468 Slayton et al. Jul 2015 A1
20150217141 Barthe et al. Aug 2015 A1
20150238258 Palero et al. Aug 2015 A1
20150297188 Konofagou Oct 2015 A1
20150321026 Branson et al. Nov 2015 A1
20150360058 Barthe et al. Dec 2015 A1
20150374333 Barthe et al. Dec 2015 A1
20150375014 Slayton et al. Dec 2015 A1
20160001097 Cho et al. Jan 2016 A1
20160016015 Slayton et al. Jan 2016 A1
20160027994 Toda et al. Jan 2016 A1
20160151618 Powers et al. Jun 2016 A1
20160158580 Slayton et al. Jun 2016 A1
20160175619 Lee et al. Jun 2016 A1
20160206335 Slayton Jul 2016 A1
20160206341 Slayton Jul 2016 A1
20160256675 Slayton Sep 2016 A1
20160296769 Barthe et al. Oct 2016 A1
20160310444 Dobak, III Oct 2016 A1
20160361571 Bernabei Dec 2016 A1
20160361572 Slayton Dec 2016 A1
20170028227 Emery et al. Feb 2017 A1
20170043190 Barthe et al. Feb 2017 A1
20170050019 Ron Edoute et al. Feb 2017 A1
20170080257 Paunescu et al. Mar 2017 A1
20170100585 Hall et al. Apr 2017 A1
20170119345 Levien et al. May 2017 A1
20170136263 Reil May 2017 A1
20170209201 Slayton et al. Jul 2017 A1
20170209202 Friedrichs et al. Jul 2017 A1
20170304654 Blanche et al. Oct 2017 A1
20170368574 Sammoura Dec 2017 A1
20180001113 Streeter Jan 2018 A1
20180015308 Reed et al. Jan 2018 A1
20180043147 Slayton Feb 2018 A1
20180099162 Bernabei Apr 2018 A1
20180099163 Bernabei Apr 2018 A1
20180126190 Aviad et al. May 2018 A1
20180154184 Kong et al. Jun 2018 A1
20180207450 Sanchez et al. Jul 2018 A1
20180272156 Slayton et al. Sep 2018 A1
20180272157 Barthe et al. Sep 2018 A1
20180272158 Barthe et al. Sep 2018 A1
20180272159 Slayton et al. Sep 2018 A1
20180317884 Chapelon et al. Nov 2018 A1
20180333595 Barthe et al. Nov 2018 A1
20180360420 Vortman et al. Dec 2018 A1
20190000498 Barthe et al. Jan 2019 A1
20190009110 Gross et al. Jan 2019 A1
20190009111 Myhr et al. Jan 2019 A1
20190022405 Greenbaum et al. Jan 2019 A1
20190038921 Domankevitz Feb 2019 A1
20190060675 Krone et al. Feb 2019 A1
20190091490 Alexander et al. Mar 2019 A1
20190142380 Emery et al. May 2019 A1
20190143148 Slayton May 2019 A1
20190184202 Zereshkian et al. Jun 2019 A1
20190184203 Slayton et al. Jun 2019 A1
20190184205 Slayton et al. Jun 2019 A1
20190184207 Barthe et al. Jun 2019 A1
20190184208 Barthe et al. Jun 2019 A1
20190224501 Burdette Jul 2019 A1
20190262634 Barthe et al. Aug 2019 A1
20190282834 Zawada et al. Sep 2019 A1
20190290939 Watson et al. Sep 2019 A1
20190350562 Slayton et al. Nov 2019 A1
20190366126 Pahk et al. Dec 2019 A1
20190366127 Emery Dec 2019 A1
20190366128 Slayton et al. Dec 2019 A1
20200094083 Slayton et al. Mar 2020 A1
20200100762 Barthe et al. Apr 2020 A1
20200129759 Schwarz Apr 2020 A1
20200171330 Barthe et al. Jun 2020 A1
20200179727 Slayton et al. Jun 2020 A1
20200179729 Slayton et al. Jun 2020 A1
20200188703 Barthe et al. Jun 2020 A1
20200188704 Barthe et al. Jun 2020 A1
20200206072 Capelli et al. Jul 2020 A1
20200222728 Khokhlova et al. Jul 2020 A1
20210038925 Emery Feb 2021 A1
Foreign Referenced Citations (192)
Number Date Country
2460061 Nov 2001 CN
1734284 Dec 2009 CN
104027893 Sep 2014 CN
4029175 Mar 1992 DE
10140064 Mar 2003 DE
10219297 Nov 2003 DE
10219217 Dec 2004 DE
20314479 Dec 2004 DE
0142215 May 1984 EP
0344773 Dec 1989 EP
1479412 Nov 1991 EP
0473553 Apr 1992 EP
670147 Feb 1995 EP
0661029 Jul 1995 EP
724894 Feb 1996 EP
763371 Nov 1996 EP
1044038 Oct 2000 EP
1050322 Nov 2000 EP
1234566 Aug 2002 EP
1262160 Dec 2002 EP
0659387 Apr 2003 EP
1374944 Jan 2004 EP
1028660 Jan 2008 EP
1874241 Jan 2008 EP
1362223 May 2008 EP
1750804 Jul 2008 EP
1283690 Nov 2008 EP
1811901 Apr 2009 EP
1785164 Aug 2009 EP
2230904 Sep 2010 EP
1501331 Jun 2011 EP
2066405 Nov 2011 EP
2474050 Jul 2012 EP
2709726 Nov 2015 EP
1538980 Jan 2017 EP
3124047 Jan 2017 EP
2897547 Nov 2017 EP
2173261 Aug 2018 EP
3417911 Dec 2018 EP
2532851 Sep 1983 FR
2685872 Jan 1992 FR
2672486 Aug 1992 FR
2703254 Mar 1994 FR
2113099 Aug 1983 GB
102516 Jan 1996 IL
112369 Aug 1999 IL
120079 Mar 2001 IL
63036171 Feb 1988 JP
03048299 Mar 1991 JP
3123559 May 1991 JP
03136642 Jun 1991 JP
4089058 Mar 1992 JP
04150847 May 1992 JP
7080087 Mar 1995 JP
07505793 Jun 1995 JP
7184907 Jul 1995 JP
7222782 Aug 1995 JP
09047458 Feb 1997 JP
9108288 Apr 1997 JP
9503926 Apr 1997 JP
11123226 May 1999 JP
11505440 May 1999 JP
11506636 Jun 1999 JP
10248850 Sep 1999 JP
2000126310 May 2000 JP
2000166940 Jun 2000 JP
2000233009 Aug 2000 JP
2001-46387 Feb 2001 JP
2001136599 May 2001 JP
2001170068 Jun 2001 JP
2002505596 Feb 2002 JP
2002078764 Mar 2002 JP
2002515786 May 2002 JP
2002537013 May 2002 JP
2002521118 Jul 2002 JP
2002537939 Nov 2002 JP
2003050298 Jul 2003 JP
2003204982 Jul 2003 JP
2004-504898 Feb 2004 JP
2004-507280 Mar 2004 JP
2004154256 Mar 2004 JP
2004-509671 Apr 2004 JP
2004-512856 Apr 2004 JP
2004147719 May 2004 JP
2005503388 Feb 2005 JP
2005527336 Sep 2005 JP
2005323213 Nov 2005 JP
2006520247 Sep 2006 JP
2008515559 May 2008 JP
2009518126 May 2009 JP
2010517695 May 2010 JP
2001-0019317 Mar 2001 KR
1020010024871 Mar 2001 KR
2002-0038547 May 2002 KR
100400870 Oct 2003 KR
20060121267 Nov 2006 KR
1020060113930 Nov 2006 KR
1020070065332 Jun 2007 KR
1020070070161 Jul 2007 KR
1020070098856 Oct 2007 KR
1020070104878 Oct 2007 KR
1020070114105 Nov 2007 KR
1020000059516 Apr 2012 KR
10-2013-0124598 Nov 2013 KR
10-1365946 Feb 2014 KR
386883 Sep 2000 TW
201208734 Mar 2012 TW
WO9312742 Jul 1993 WO
WO9524159 Sep 1995 WO
WO9625888 Aug 1996 WO
WO9634568 Nov 1996 WO
WO9639079 Dec 1996 WO
WO9735518 Oct 1997 WO
WO9832379 Jul 1998 WO
WO9852465 Nov 1998 WO
WO9933520 Jul 1999 WO
WO9939677 Aug 1999 WO
WO9949788 Oct 1999 WO
WO200006032 Feb 2000 WO
WO0015300 Mar 2000 WO
WO0021612 Apr 2000 WO
WO0048518 Aug 2000 WO
WO0053113 Sep 2000 WO
WO200071021 Nov 2000 WO
WO0128623 Apr 2001 WO
WO01045550 Jun 2001 WO
WO0182777 Nov 2001 WO
WO0182778 Nov 2001 WO
WO0187161 Nov 2001 WO
WO01080709 Nov 2001 WO
WO2001087161 Nov 2001 WO
WO0209812 Feb 2002 WO
WO0209813 Feb 2002 WO
WO02015768 Feb 2002 WO
WO0224050 Mar 2002 WO
WO2002054018 Jul 2002 WO
WO02092168 Nov 2002 WO
WO03053266 Jul 2003 WO
WO03065347 Aug 2003 WO
WO03070105 Aug 2003 WO
WO03077833 Sep 2003 WO
WO03086215 Oct 2003 WO
WO03096883 Nov 2003 WO
WO03099177 Dec 2003 WO
WO03099382 Dec 2003 WO
WO03101530 Dec 2003 WO
WO2004000116 Dec 2003 WO
WO2004080147 Sep 2004 WO
WO2004110558 Dec 2004 WO
WO2005011804 Feb 2005 WO
WO2005065408 Jul 2005 WO
WO2005065409 Jul 2005 WO
WO2005090978 Sep 2005 WO
WO2005113068 Dec 2005 WO
WO2006042163 Apr 2006 WO
WO2006036870 Apr 2006 WO
WO2006042168 Apr 2006 WO
WO2006042201 Apr 2006 WO
WO2006065671 Jun 2006 WO
WO2006082573 Aug 2006 WO
WO2006104568 Oct 2006 WO
WO2007067563 Jun 2007 WO
WO2008036479 Mar 2008 WO
WO2008036622 Mar 2008 WO
WO2008144274 Nov 2008 WO
WO2009013729 Jan 2009 WO
WO2009149390 Oct 2009 WO
WO2012134645 Oct 2012 WO
WO2013048912 Apr 2013 WO
WO2013178830 Dec 2013 WO
WO2014045216 Mar 2014 WO
WO2014055708 Apr 2014 WO
WO2014057388 Apr 2014 WO
WO2014127091 Aug 2014 WO
WO2015160708 Oct 2015 WO
WO2016054155 Apr 2016 WO
WO2016115363 Jul 2016 WO
WO2017127328 Jul 2017 WO
WO2017149506 Sep 2017 WO
WO2017165595 Sep 2017 WO
WO 2017212489 Dec 2017 WO
WO2017212489 Dec 2017 WO
WO2018035012 Feb 2018 WO
WO2018158355 Sep 2018 WO
WO2019008573 Jan 2019 WO
WO2019147596 Aug 2019 WO
WO 2019147596 Aug 2019 WO
WO2019164836 Aug 2019 WO
WO2020009324 Jan 2020 WO
WO2020075906 Apr 2020 WO
WO2020080730 Apr 2020 WO
WO2020121307 Jun 2020 WO
Non-Patent Literature Citations (382)
Entry
US 10,398,895 B2, 09/2019, Schwarz (withdrawn)
Adams et al., “High Intensity Focused Ultrasound Ablation of Rabbit Kidney Tumors” Sonablate High-Intensity Focused Ultrasound device; Journal of Endourology vol. 10, No. 1, (Feb. 1996).
Agren, Magnus S. et al., Collagenase in Wound Healing: Effect of Wound Age and Type. The Journal of Investigative Dermatology, vol. 99/No. 6, (Dec. 1992).
Alam, M., “The future of noninvasive procedural dermatology”. Semin Cutan Med Surg. Mar. 2013; 32(1):59-61.
Alam, M., et al., “Ultrasound tightening of facial and neck skin: a rater-blinded prospective cohort study”. J Am Acad Dermatol, 2010. 62(2): p. 262-9.
Alexiades-Armenakas, M., “Ultrasound Technologies for Dermatologic Techniques”. J Drugs Derm. 2014. 12 (11): p. 1305.
Alster, T.S., et al., “Noninvasive lifting of arm, thigh, and knee skin with transcutaneous intense focused ultrasound”. Dermatol Surg, 2012. 38(5): p. 754-9.
Alster, Tinas S., Tanzi, Elizabeth L., “Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85.
Arosarena, O., “Options and Challenges for Facial Rejuvenation in Patients With Higher Fitzpatrick Skin Phototypes”. JAMA Facial Plastic Surgery, 2015.
Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600.
Barthe et al., “Ultrasound therapy system and ablation results utilizing miniature imaging/therapy arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3.
Bozec, Laurent et al., Thermal Denaturation Studies of Collagen by Microthermal Analysis and Atomic Force Microscopy, Biophysical Journal, vol. 101, pp. 228-236. (Jul. 2001).
Brobst, R.W., et. al., “Noninvasive Treatment of the Neck”. Facial Plast Surg Clin North Am, 2014. 22(2): p. 191-202.
Brobst, R.W., et., al., “Ulthera: initial and six month results”. Facial Plast Surg Clin North Am, 2012. 20(2): p. 163-76.
Brown J A et al: “Fabrication and performance of 40-60 MHz annular arrays”, 2003 IEEE Ultrasonics Symposium Proceedings. Honolulu, Hawaii, Oct. 5-8, 2003; [IEEE Ultrasonics Symposium Proceedings], New York, NY : IEEE, US, vol. 1, Oct. 5, 2003 (Oct. 5, 2003), pp. 869-872.
Calderhead et al., “One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell” Laser Therapy 17.3: 141-148 (2008).
Carruthers et al., “Consensus Recommendations for Combined Aesthetic Interventions in the Face Using Botulinum Toxin, Fillers, and Energy-Based Devices” Dermatol Surg 2016 (pp. 1-12).
Casabona, G., et. al., “Microfocused Ultrasound with Visualization and Calcium Hydroxylapatite for Improving Skin Laxity and Cellulite Appearance”; Plast Reconstr Surg Glob Open. Jul. 25, 2017;5(7):e1388, 8 pages.
Casabona, G., et. al., “Microfocused Ultrasound With Visualization and Fillers for Increased Neocollagenesis: Clinical and Histological Evaluation”. Dermatol Surg 2014;40:S194-S198.
Chan, N.P., et al., “Safety study of transcutaneous focused ultrasound for non-invasive skin tightening in Asians”. Lasers Surg Med, 2011. 43(5): p. 366-75.
Chapelon et al., “Effects of Cavitation in the High Intensity Therapeutic Ultrasound”, Ultrasonics Symposium—1357 (1991).
Chapelon, et al., “Thresholds for Tissue Ablation by Focused Ultrasound” (1990).
Chen, L. et al., “Effect of Blood Perfusion on the ablation of liver parenchyma with high intensity focused ultrasound,” Phys. Med. Biol; 38:1661-1673; 1993b.
Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectrometry” Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468.
Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444, 456.
Damianou et al., “Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery,” 1993 IEEE Ultrasound Symposium, pp. 1199-1202.
Daum et al., Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438.
Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 Ultrasonics Symposium, pp. 921-924.
Dayan, S.H., et al., “Prospective, Multi-Center, Pivotal Trial Evaluating the Safety and Effectiveness of Micro-Focused Ultrasound with Visualization (MFU-V) for Improvement in Lines and Wrinkles of the Décolletage”. Plast Reconstr Surg. Oct. 2014; 134(4 Suppl 1 ):123-4.
Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on pp. 1-4 of the Information Disclosure Statement herein (English translation, English translation certification, and Korean decision included).
Delon Martin, C., et al., “Venous Thrombosis Generation by Means of High-Intensity Focused Ultrasound” Ultrasound in Med. & Biol., vol. 21, No. 1, pp. 113-119 (1995).
Dierickx, Christine C., “The Role of Deep Heating for Noninvasive Skin Rejuvenation” Lasers in Surgery and Medicine 38:799-807 (2006).
Dobke, M.K., et al., “Tissue restructuring by energy-based surgical tools”. Clin Plast Surg, 2012. 39(4): p. 399-408.
Dong, Yuan-Lin et al., “Effect of Ibuprofen on the Inflammatory Response to Surgical Wounds” The Journal of Trauma, vol. 35, No. 3. (1993).
Driller et al., “Therapeutic Applications of Ultrasound: A Review” IEEE Engineering in Medicine and Biology; (Dec. 1987) pp. 33-40.
Dvivedi, Sanjay, et al. “Effect of Ibuprofen and diclofenac sodium on experimental wound healing” Indian Journal of Experimental Biology, vol. 35, pp. 1243-1245. (Nov. 1997).
Fabi, S.G., “Microfocused Ultrasound With Visualization for Skin Tightening and Lifting: My Experience and a Review of the Literature”. Dermatol Surg. Dec. 2014; 40 Suppl 12:S164-7.
Fabi, S.G., “Noninvasive skin tightening: focus on new ultrasound techniques”. Clin Cosmet Investig Dermatol. Feb. 5, 2015; 8:47-52.
Fabi, S.G., et al., “A prospective multicenter pilot study of the safety and efficacy of microfocused ultrasound with visualization for improving lines and wrinkles of the décolleté”. Dermatol Surg. Mar. 2015; 41(3):327-35.
Fabi, S.G., et al., “Evaluation of microfocused ultrasound with visualization for lifting, tightening, and wrinkle reduction of the decolletage”. J Am Acad Dermatol, 2013. 69(6): p. 965-71.
Fabi, S.G., et al., “Future directions in cutaneous laser surgery”. Dermatol Clin, 2014. 32(1): p. 61-9.
Fabi, S.G., et al., “Retrospective Evaluation of Micro-focused Ultrasound for Lifting and Tightening the Face and Neck”. Dermatol Surg, 2014.
Friedmann D.P., “Comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face”. Aesthet Surg J. Mar. 2015;35(3):NP81-2.
Friedmann, D.P., et. al., “Combination of intense pulsed light, Sculptra, and Ultherapy for treatment of the aging face”. J Cosmet Dermatol, 2014. 13(2): p. 109-18.
Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” J. Neurosurg., 11:471-478; 1954.
Fujimoto, et al., “A New Cavitation Suppression Technique for Local Ablation Using High-Intensity Focused Ultrasound” Ultrasonics Symposium—1629 (1995).
Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9, No. 1.
Gold, M.H., et al., “Use of Micro-Focused Ultrasound with Visualization to Lift and Tighten Lax Knee Skin”. J Cosmet Laser Ther, 2014: p. 1-15.
Goldberg, D.J., et. al., “Safety and Efficacy of Microfocused Ultrasound to Lift, Tighten, and Smooth the Buttocks”. Dermatol Surg 2014; 40:1113-1117.
Greene, R.M., et al., “Skin tightening technologies”. Facial Plast Surg. Feb. 2014; 30(1):62-7.
Greenhalgh, David G., “Wound healing and diabetes mellitus” Clinics in Plastic Surgery 30; 37-45. (2003).
Guo, S. et al., “Factors Affecting Wound Healing” Critical Reviews in Oral Biology & Medicine, J Dent Res 89(3), pp. 219-229. (2010).
Haar, G.R. et al., “Tissue Destruction with Focused Ultrasound in Vivo,” Eur. Urol. 23 (suppl. 1):8-11; 1993.
Hantash, Basil M. et al., “Bipolar Fractional Radiofrequency Treatment Induces Neoelastogenesis and Neocollagenesis” Lasers in Surgery and Medicine 41:1-9 (2009).
Hantash, Basil M. et al., “In Vivo Histological Evaluation of a Novel Ablative Fractional Resurfacing Device” Lasers in Surgery and Medicine 39:96-107 (2007).
Harris, M.O., “Safety of Microfocused Ultrasound With Visualization in Patients With Fitzpatrick Skin Phototypes III to VI”. JAMA Facial Plast. Surg, 2015.
Hart, et. al., “Current Concepts in the Use of PLLA: Clinical Synergy Noted with Combined Use of Microfocused Ultrasound and Poly-I-Lactic Acid on the Face, Neck, and Décolletage”. Amer. Soc. Plast. Surg. 2015. 136; 180-187S.
Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” advanced in Polymer Science, 2000, pp. 37-65, vol. 153.
Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.
Hexsel et al., “A Validated Photonumeric Cellulite Severity Scale”; J Eur Acad Dermatol Venereol. May 2009; 23(5):523-8, 6 pages.
Hitchcock, T.M. et al., “Review of the safety profile for microfocused ultrasound with Visualization”. Journal of Cosmetic Dermatology, 13, 329-335. (2014).
Husseini et al, “The Role of Cavitation in Acoustically Activated Drug Delivery,” J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2).
Husseini et al. “Investigating the mechanism of acoustically activated uptake of drugs from Pluronic micelles,” BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6.
Hynynen et al., Temperature Distributions During Local Ultrasound Induced Hyperthermia In Vivo, Ultrasonics Symposium—745 (1982).
Jeffers et al., “Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms,” 1993 IEEE Ultrasonics Symposium, pp. 925-928.
Jenne, J., et al., “Temperature Mapping for High Energy US-Therapy”, 1994 Ultrasonics Symposium, pp. 1879-1882.
Jeong, K.H., et al., “Neurologic complication associated with intense focused ultrasound”. J Cosmet Laser Ther, 2013.
Johnson, S.A., et al., “Non-lntrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic Temperature Tomography”, Ultrasonics Symposium Proceedings, pp. 977-982. (1977).
Ketterling J. A. et al.: “Design and fabrication of a 40-MHz annular array transducer”, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, IEEE, US, vol. 52, No. 4, Apr. 1, 2005 (Apr. 1, 2005), pp. 672-681.
Kim, H.J., et al., “Coagulation and ablation patterns of high-intensity focused ultrasound on a tissue mimicking phantom and cadaveric skin”. Laser Med Sci. Sep. 4, 2015.
Kornstein, A.N., “Ulthera for silicone lip correction”. Plast Reconstr Surg, 2012. 129(6): p. 1014e-1015e.
Kornstein, A.N., “Ultherapy shrinks nasal skin after rhinoplasty following failure of conservative measures”. Plast Reconstr Surg, 2013. 131(4): p. 664e-6e.
Krischak, G.D., et al., “The effects of non-steroidal anti-inflammatory drug application on incisional wound healing in rats” Journal of Wound Care, vol. 6, No. 2, (Feb. 2007).
Laubach, H.J., et al., “Confined Thermal Damage with Intense Ultrasound (IUS)” [abstr.] American Society for Laser Medicine and Surgery Abstracts, p. 15 #43 (Apr. 2006).
Laubach, H.J., et al., “Intense focused ultrasound: evaluation of a new treatment modality for precise microcoagulation within the skin”. Dermatol Surg, 2008. 34(5): p. 727-34.
Lee, H.J., et al., “The efficacy and safety of intense focused ultrasound in the treatment of enlarged facial pores in Asian skin”. J Dermatolog Treat, 2014.
Lee, H.S., et al., “Multiple Pass Ultrasound Tightening of Skin Laxity of the Lower Face and Neck”. Dermatol Surg, 2011.
Lin, Sung-Jan, et al., “Monitoring the thermally induced structural transitions of collagen by use of second-harmonic generation microscopy” Optics Letters, vol. 30, No. 6, (Mar. 15, 2005).
MacGregor J.L., et. al., “Microfocused Ultrasound for Skin Tightening”. Semin Cutan Med Surg 32:18-25. (2013).
Madersbacher, S. et al., “Tissue Ablation in Benign Prostatic Hyperplasia with High Intensity Focused Ultrasound,” Dur. Urol., 23 (suppl. 1):39-43; 1993.
Makin et al, “B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.
Makin et al., “Confirmed Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays,” 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004.
Makin et al., “Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging,” UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).
Manohar et al, “Photoacoustic mammography laboratory prototype: imaging of breast tissue phantoms,” Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.
Mast et al, “Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling and Experiments,” J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4).
Meshkinpour, Azin, et al., “Treatment of Hypertrophic Scars and Keloids With a Radiofrequency Device: A Study of Collagen Effects” Lasers in Surgery and Medicine 37:343-349 (2005).
Microchip microID 125 kHz EFID System Design Guide, Microchip Technology Inc. (2004).
Minkis, K., et. al., “Ultrasound skin tightening”. Dermatol Clin, 2014. 32(1): p. 71-7.
Mitragotri, S., “Healing sound: the use of ultrasound in drug delivery and other therapeutic applications,” Nature Reviews; Drug Delivery, pp. 255-260, vol. 4 (Mar. 2005).
Mosser, David M. et al., “Exploring the full spectrum of macrophage activation” Nat Rev Immunol; 8(12): 958-969. (Dec. 2008).
Murota, Sei-Itsu, et al., “Stimulatory Effect of Prostaglandins on the Production of Hexosamine-Containing Substances by Cultured Fibroblasts (3) Induction of Hyaluronic Acid Synthetase by Prostaglandin” Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo—173, Japan. (Nov. 1977, vol. 14, No. 5).
Murota, Sei-Itsu, et al., “The Stimulatory Effect of Prostaglandins on Production of Hexosamine-Containing Substances by Cultured Fibroblasts” Department of Pharmacology, Tokyo Metropolitan Institute of Gerontology, Itabashiku, Tokyo—173, Japan. (Aug. 1976, vol. 12, No. 2).
Nestor, M.S. et. al., “Safety and Efficacy of Micro-focused Ultrasound Plus Visualization for the Treatment of Axillary Hyperhidrosis”. J Clin Aesthet Dermatol, 2014. 7(4): p. 14-21.
Oni, G., et. al. “Response to ‘comments on evaluation of microfocused ultrasound system for improving skin laxity and tightening in the lower face’”. Aesthet Surg J. Mar. 2015;35(3):NP83-4.
Oni, G., et. al., “Evaluation of a Microfocused Ultrasound System for Improving Skin Laxity and Tightening in the Lower Face”. Aesthet Surg J, 2014. 38:861-868.
Pak, C.S., et. al., “Safety and Efficacy of Ulthera in the Rejuvenation of Aging Lower Eyelids: A Pivotal Clinical Trial”. Aesthetic Plast Surg, 2014.
Paradossi et al., “Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications,” Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14.
Priizker, R.N., et. al, “Updates in noninvasive and minimally invasive skin tightening”. Semin Cutan Med Surg. Dec. 2014;33(4):182-7.
Pritzker, R.N., et. al., “Comparison of different technologies for noninvasive skin tightening”. Journal of Cosmetic Dermatology, 13, 315-323. (2014).
Rappolee, Daniel A., et al., “Wound Macrophages Express TGF and Other Growth Factors in Vivo: Analysis by mRNA Phenotyping” Science, vol. 241, No. 4866 (Aug. 1988).
Reid, Gavin, et al., “Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions,” Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.
Righetti et al, “Elastographic Characterization of HIFU-lnduced Lesions in Canine Livers,” 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113.
Rokhsar, C., et. al., “Safety and efficacy of microfocused ultrasound in tightening of lax elbow skin”. Dermatol Surg. 2015; 41(7):821-6.
Rosenberg, Carol S. “Wound Healing in the Patient with Diabetes Mellitus” Nursing Clinics of North America, vol. 25, No. 1, (Mar. 1990).
Saad et al., “Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors,” Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992).
Sabet-Peyman, E.J. et. al., “Complications Using Intense Ultrasound Therapy to Treat Deep Dermal Facial Skin and Subcutaneous Tissues”. Dermatol Surg 2014; 40:1108-1112.
Sandulache, Vlad C. et al., “Prostaglandin E2 inhibition of keloid fibroblast migration, contraction, and transforming growth factor (TGF)—B1—induced collagen synthesis” Wound Rep Reg 15 122-133, 2007. (2007).
Sanghvi, N.T., et al., “Transrectal Ablation of Prostate Tissue Using Focused Ultrasound,” 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210.
Sasaki, G.H. et. al., “Clinical Efficacy and Safety of Focused-Image Ultrasonography: A 2-Year Experience”. Aesthet Surg J, 2012.
Sasaki, G.H. et. al., “Microfocused Ultrasound for Nonablative Skin and Subdermal Tightening to the Periorbitum and Body Sites: Preliminary Report on Eighty-Two Patients”. Journal of Cosmetics, Dermatological Sciences and Applications, 2012, 2, 108-116.
Sassen, Sander, “ATI's R520 architecture, the new king of the hill?” http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages.
Seip, Ralf, et al., “Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fields,” IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.
Seip, Ralf, et al., “Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound,” IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839.
Simon et al., “Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy,” Ultrasound in Med. & Biol. vol. 19, No. 2, pp. 123-125 (1993).
Sklar, L.R., et al., “Use of transcutaneous ultrasound for lipolysis and skin tightening: a review”. Aesthetic Plast Surg, 2014. 38(2): p. 429-41.
Smith, Nadine Barrie, et al., “Non-invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques”, 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3.
Sonocare, Inc. Therapeutic Ultrasound System Model CST-100 Instruction Manual (1985).
Suh, D.H., et. al., “A intense-focused ultrasound tightening for the treatment of infraorbital laxity”. J Cosmet Laser Ther, 2012. 14(6): p. 290-5.
Suh, D.H., et. al., “Comparative histometric analysis of the effects of high-intensity focused ultrasound and radiofrequency on skin”. J Cosmet Laser Ther. Mar. 24, 2015:1-7.
Suh, D.H., et. al., “Intense Focused Ultrasound Tightening in Asian Skin: Clinical and Pathologic Results” American Society for Dermatologic Surgery, Inc.; 37:1595-1602. (2011).
Surry et al., “Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging,” Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49.
Syka J. E. P. et al., “Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectrometry,” Proceedings of the National Academy of Sciences of USA, National Academy of Science, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.
Talbert, D. G., “An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays,” UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67.
Tata et al., “Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions,” American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555.
Ueno, S., et al., “Ultrasound Thermometry in Hyperthermia”, 1990 Ultrasonic Symposium, pp. 1645-1652.
Verhofstad, Michiel H.J. et al., “Collagen Synthesis in rat skin and ileum fibroblasts is affected differently by diabetes-related factors” Int. J. Exp. Path. (1998), 79, 321-328.
Wang, H., et al., “Limits on Focused Ultrasound for Deep Hyperthermia”, 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.
Wasson, Scott, “NVIDIA's GeForce 7800 GTX graphics processor Power MADD,” http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages.
Webster et al. “The role of ultrasound-induced cavitation in the ‘in vitro’ stimulation of collagen synthesis in human fibroblasts”; Ultrasonics pp. 33-37(Jan. 1980).
Weiss, M., “Commentary: noninvasive skin tightening: ultrasound and other technologies: where are we in 2011?” Dermatol Surg, 2012. 38(1): p. 28-30.
White et al “Selective Creating of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy,” Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1 (pp. 22-29).
White, W. M., et al., “Selective Transcutaneous Delivery of Energy to Facial Subdermal Tissues Using the Ultrasound Therapy System” [abstr]. American Society for Laser Medicine and Surgery Abstracts, p. 37 #113 (Apr. 2006).
White, W. Matthew, et al., “Selective Transcutaneous Delivery of Energy to Porcine Soft Tissues Using Intense Ultrasound (IUS)” Lasers in Surgery and Medicine 40:67-75 (2008).
Woodward, J.A., et. al. “Safety and Efficacy of Combining Microfocused Ultrasound With Fractional CO2 Laser Resurfacing for Lifting and Tightening the Face and Neck”. Dermatol Surg, Dec. 2014 40:S190-S193.
Zelickson, Brian D. et al., “Histological and Ultrastructural Evaluation of the Effects of a Radiofrequency-Based Nonablative Dermal Remodeling Device, A Pilot Study” Arch Dermatol, vol. 140, (Feb. 2004).
Ulthera, Inc., Petition for Inter Partes Review filed Jul. 19, 2016 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 63 pages (Filed Jul. 19, 2016).
Ulthera Exhibit 1001, U.S. Pat. No. 6,113,559 to Klopotek, filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1002, Patent file history of U.S. Pat. No. 6,113,559 Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1003, Declaration of Expert Witness Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1004, Curriculum Vitae of Mark E. Schafer, Ph.D. filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1005, International PCT Publication WO96/34568 Knowlton filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1006, French Patent No. 2,672,486, Technomed patent filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1007, English translation of French Patent No. 2,672,486, Technomed filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1008, International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1009, English translation of International PCT Publication WO93/12742, Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1010, U.S. Pat. No. 5,601,526, which claims priority to Technomed PCT filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1011, Patent file history for European Patent Application No. 98964890.2, Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1012, Translator Declaration filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1013, U.S. Pat. No. 5,230,334 to Klopotek filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1014, U.S. Pat. No. 5,755,753 to Knowlton filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1015, Excerpts from The American Medical Association Encyclopedia of Medicine (1989) filed Jul. 19, 2016 in re IPR2016-01459.
Ulthera Exhibit 1016, The Simultaneous Study of Light Emissions and Shock Waves Produced by Cavitation Bubbles, G. Gimenez, J. Acoust. Soc. Am. 71(4), Apr. 1982, pp. 839-847 (filed Jul. 19, 2016 in re IPR2016-01459).
Ulthera Exhibit 1017, Excerpts from Gray's Anatomy (1995) (filed Jul. 19, 2016 in re IPR2016-01459).
Ulthera Exhibit 1018, Anatomy of the Superficial Venous System, Comjen G.M., Dermatol. Surg., 1995; 21:35-45 (filed Jul. 19, 2016 in re IPR2016-01459).
Ulthera Exhibit 1019, Section 2.6 from Ultrasonics Theory and Application, by G.L. Gooberman (Hart Publishing Co., 1969) (filed Jul. 19, 2016 in re IPR2016-01459).
Ulthera Exhibit 1020, Deep Local Hyperthermia for Cancer Therapy: External Electromagnetic and Ultrasound Techniques, A.Y. Cheung and A. Neyzari, Cancer Research (Suppl.), vol. 44, pp. 4736-4744 (1984) (filed Jul. 19, 2016 in re IPR2016-01459).
Decision on Institution of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 20 pages [011 ] (Dated Jan. 23, 2017).
Dermafocus Response to Institution of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 73 pages [018] (Dated Apr. 26, 2017).
Dermafocus Exhibit List in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 5 pages [019] (Dated Apr. 26, 2017).
Dermafocus Exhibit 2002, Declaration of Mark Palmeri, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 136 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2003, Deposition of Dr. Mark Schafer, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 327 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2004, Amendment No. 4 to Ulthera Form S-1, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 308 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2005, Excerpt from Churchill Livingstone, Gray's Anatomy (38th ed. 1995), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2006, Bo Eklof et al., “Revision of the CEAP Classification for Chronic Venous Disorders: Consensus Statement,” ACTA FAC MED NAISS, vol. 25, No. 1 (2008), 3-10 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2007, WebMD, “Varicose Veins and Spider Veins” downloaded from http://www.webmd.com/skin-problems-andtreatments/guide/varicose-spider-veins#1 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 3 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2008, John M. Porter et al, “Reporting Standards in Venous Disease: An Update,” Journal of Vascular Surgery, vol. 21, No. 4 (1995), 635-645 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 11 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2009, Kullervo Hynynen, “Review of Ultrasound Therapy,” 1997 Ultrasonics Symposium (1997), 1305-1313, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 9 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2010, A.G. Visioli et al, “Preliminary Results of a Phase I Dose Escalation Clinical Trial Using Focused Ultrasound in the Treatment of Localised Tumours,” European Journal of Ultrasound, vol. 9 (1999), 11-18, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 8 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2011, U.S. Pat. No. 5,143,063, issued on Sep. 1, 1992, Fellner, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2012, Hugh G. Beebe et al, “Consensus Statement: Classification and Grading of Chronic Venous Disease in the Lower Limbs,” European Journal of Vascular and Endovascular Surgery, vol. 12 (1996), 487-492, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2013, Excerpt from Mosby's Medical Dictionary (3rd ed. 1990), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2014, Excerpt from Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health (5th ed. 1992), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2015, David J. Tibbs et al, Varicose Veins, Venous Disorders, and Lymphatic Problems in the Lower Limbs (1997), Chapter 4: Clinical Patterns of Venous Disorder I, 47-67, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 24 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2016, Mitchel P. Goldman et al., Varicose Veins and Telangiectasias (2nd ed. 1999), Chapter 22: Treatment of Leg Telangiectasias with Laser and High-Intensity Pulsed Light, 470-497, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 31 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2017, Email from Anderson to Klopotek dated May 25, 2004, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 1 page (Filed Apr. 26, 2017).
Dermafocus Exhibit 2018, List of Klopotek Patents, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 411 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2019, Declaration of Peter Klopotek Civil Action 15-cv-654-SLR, dated Nov. 2, 2016, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 1 page (Filed Apr. 26, 2017).
Dermafocus Exhibit 2020, “Our Technology,” downloaded from http://jobs.ulthera.com/about on Apr. 10, 2017, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2021, C. Damianou and K. Hynynen, “Focal Spacing and Near-Field Heating During Pulsed High Temperature Ultrasound Therapy,” Ultrasound in Medicine & Biology, vol. 19, No. 9 (1993), 777-787, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 11 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2022, Excerpt from Mosby's Medical Dictionary (5th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 5 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2023, Excerpt from Miller-Keane Encyclopedia & Dictionary of Medicine, Nursing, & Allied Health (6th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 7 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2024, Excerpt from Stedman's Concise Medical Dictionary (3 rd ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 4 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2025, Excerpt from Taber's Cyclopedic Medical Dictionary (18th ed. 1997), in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 9 pages (Filed Apr. 26, 2017).
Dermafocus Exhibit 2026, Bo Eklof et al, “Revision of the CEAP Classification for Chronic Venous Disorders: Consensus Statement,” Journal of Vascular Surgery, vol. 40, No. 6 (2004), 1248-1252.el, in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 6 pages (Filed Apr. 26, 2017).
Ulthera, Inc., Reply in Support of Petition for Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 33 pages (Filed Aug. 2, 2017).
Ulthera Exhibit 1022, Use of the Argon and Carbon Dioxide Lasers for Treatment of Superficial Venous Varicosities of the Lower Extremity, D. Apfelberg et al., Lasers in Surgery and Medicine, vol. 4.3, pp. 221-231 (1984) (filed Aug. 2, 2017 in re IPR2016-01459).
Ulthera Exhibit 1023, 532-Nanometer Green Laser Beam Treatment of Superficial Varicosities of the Lower Extremities, T. Smith et al., Lasers in Surgery and Medicine, vol. 8.2, pp. 130-134 (1988) (filed Aug. 2, 2017 in re IPR2016-01459).
Ulthera Exhibit 1024, Deposition Transcript of Dr. Mark Palmeri on Jul. 11, 2017 (filed Aug. 2, 2017 in re IPR2016-01459).
Ulthera Exhibit 1025, Ulthera Oral Proceeding Demonstrative Slides (filed Oct. 2, 2017 in re IPR2016-01459).
Dermafocus Exhibit 2027, DermaFocus Oral Proceeding Demonstrative Slides (filed Oct. 2, 2017 in re IPR2016-01459).
PTAB Record of Oral Hearing held Oct. 4, 2017 in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 67 pages (PTAB Document sent to Ulthera on Nov. 1, 2017).
Final Written Decision of Inter Partes Review in Re U.S. Pat. No. 6,113,559; IPR2016-01459; 37 pages [030] (Entered Jan. 19, 2018).
Ulthera, Inc., Petitioner Notice of Appeal to Federal Circuit 2018-1542 re: IPR2016-01459; 4 pages from [001] (no appendices) (Filed Feb. 9, 2018).
Federal Circuit Order Granting Ulthera Motion to Remand, re: 2018-1542; 4 pages [022] (Dated May 25, 2018).
Ulthera Brief (Corrected), Fed. Cir. Appeal Case 19-1006 from re: IPR2016-01459; 136 pages [030] (Dated Apr. 3, 2019).
DermaFocus Brief (Corrected), Fed. Cir. Appeal Case 19-1006 from re: IPR2016-01459; 73 pages [032] (Dated Apr. 4, 2019).
U.S. Appl. No. 16/049,365, filed Jul. 30, 2018, Energy Based Hyperhidrosis Treatment.
U.S. Appl. No. 14/628,198, filed Feb. 20, 2015, System and Method for Treating Cartilage and Injuries to Joints and Connective Tissue.
U.S. Appl. No. 13/071,298, filed Mar. 24, 2011, Visual Imaging System for Ultrasonic Probe.
U.S. Appl. No. 14/847,626, filed Sep. 8, 2015, filed Systems for Cosmetic Treatment.
U.S. Appl. No. 12/996,616, filed Jan. 12, 2011, Hand Wand for Ultrasonic Cosmetic Treatment and Imaging.
U.S. Appl. No. 16/703,019, filed Dec. 6, 2019, System and Method for Ultrasound Treatment.
U.S. Appl. No. 13/245,822, filed Sep. 26, 2011, System and Method for Cosmetic Treatment.
U.S. Appl. No. 13/245,852, filed Sep. 26, 2011, Systems for Cosmetic Treatment.
U.S. Appl. No. 13/245,864, filed Sep. 27, 2011, Methods for Non-Invasive Cosmetic Treatment of the Eye Region.
U.S. Appl. No. 13/246,117, filed Sep. 27, 2011, Methods for Non-Invasive Lifting and Tightening of the Lower Face and Neck.
U.S. Appl. No. 13/246,112, filed Sep. 27, 2011, Tissue Imaging and Treatment Method.
U.S. Appl. No. 14/193,234, filed Feb. 28, 2014, Devices and Methods for Multi-Focus Ultrasound Therapy.
U.S. Appl. No. 16/541,476, filed Aug. 15, 2019, Devices and Methods for Multi-Focus Ultrasound Therapy.
U.S. Appl. No. 15/302,436, filed Oct. 6, 2016, Band Transducer Ultrasound Therapy.
U.S. Appl. No. 15/855,949, filed Dec. 27, 2017, Band Transducer Ultrasound Therapy.
U.S. Appl. No. 16/797,393, filed Feb. 21, 2020, Band Transducer Ultrasound Therapy.
U.S. Appl. No. 15/562,384, filed Oct. 27, 2017, Systems and Methods for Cosmetic Ultrasound Treatment of Skin.
U.S. Appl. No. 16/069,319, filed Jul. 11, 2018, Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof.
U.S. Appl. No. 16/964,914, filed Jul. 24, 2020, Systems and Methods for Simultaneous Multi-Focus Ultrasound Therapy in Multiple Dimensions.
U.S. Appl. No. 16/970,772, filed Aug. 18, 2020 Systems and Methods for Combined Cosmetic Treatment of Cellulite With Ultrasound.
U.S. Appl. No. 08/950,353, filed Oct. 14, 1997, Imaging, Therapy and Temperature Monitoring Ultrasonic System.
U.S. Appl. No. 09/502,174, filed Feb. 10, 2000, Imaging, Therapy and Temperature Monitoring Ultrasonic System.
U.S. Appl. No. 10/193,419, filed Jul. 10, 2002, Imaging, Therapy and Temperature Monitoring Ultrasonic System.
U.S. Appl. No. 10/944,499, filed Sep. 16, 2004, Method and System for Ultrasound Treatment With a Multi-Directional Transducer.
U.S. Appl. No. 11/163,177, filed Oct. 7, 2005, Method and System for Treating Acne and Sebaceous Glands.
U.S. Appl. No. 10/950,112, filed Sep. 24, 2004, Method and System for Combined Ultrasound Treatment.
U.S. Appl. No. 11/163,178, filed Oct. 7, 2005, Method and System for Treating Stretch Marks.
U.S. Appl. No. 11/245,999, filed Oct. 6, 2005, System and Method for Ultra-High Frequency Ultrasound Treatment.
U.S. Appl. No. 10/944,500, filed Sep. 16, 2004, System and Method for Variable Depth Ultrasound Treatment.
U.S. Appl. No. 11/744,655, filed May 4, 2007, Imaging, Therapy and Temperature Monitoring Ultrasonic System.
U.S. Appl. No. 13/937,190, filed Jul. 8, 2013, Imaging, Therapy and Temperature Monitoring Ultrasonic System.
U.S. Appl. No. 12/135,962, filed Jun. 9, 2008, Method and System for Ultrasound Treatment With a Multi-Directional Transducer.
U.S. Appl. No. 12/792,934, filed Jun. 3, 2010, System and Method for Ultra-High Frequency Ultrasound Treatment.
U.S. Appl. No. 13/914,945, filed Jun. 11, 2013, System and Method for Ultra-High Frequency Ultrasound Treatment.
U.S. Appl. No. 12/834,754, filed Jul. 12, 2010, System and Method for Variable Depth Ultrasound Treatment.
U.S. Appl. No. 14/264,732, filed Apr. 29, 2014, System and Method for Variable Depth Ultrasound Treatment.
U.S. Appl. No. 11/126,760, filed May 11, 2005, Method and System for Three-Dimensional Scanning and Imaging.
U.S. Appl. No. 13/564,552, filed Aug. 1, 2012, Method and System for Controlled Scanning, Imaging and/or Therapy.
U.S. Appl. No. 12/437,726, filed May 8, 2009, Method and System for Combined Ultrasound Treatment.
U.S. Appl. No. 11/163,148, filed Oct. 6, 2005, Method and System for Controlled Thermal Injury of Human Superficial Tissue.
U.S. Appl. No. 13/444,688, filed Apr. 11, 2012, Customized Cosmetic Treatment.
U.S. Appl. No. 16/427,969, filed May 31, 2019, Customized Cosmetic Treatment.
U.S. Appl. No. 11/163,152, filed Oct. 6, 2005, Method and System for Treatment of Sweat Glands.
U.S. Appl. No. 13/444,485, filed Apr. 11, 2012, Methods for Treatment of Sweat Glands.
U.S. Appl. No. 13/603,159, filed Sep. 4, 2012, Methods for Treatment of Hyperhidrosis.
U.S. Appl. No. 13/603,279, filed Sep. 4, 2012, Energy Based Hyperhidrosis Treatment.
U.S. Appl. No. 13/950,728, filed Jul. 25, 2013, Energy Based Hyperhidrosis Treatment.
U.S. Appl. No. 14/571,835, filed Dec. 16, 2014, Energy Based Hyperhidrosis Treatment.
U.S. Appl. No. 15/243,081, filed Aug. 22, 2016, Energy Based Hyperhidrosis Treatment.
U.S. Appl. No. 16/049,364, filed Jul. 30, 2018, Energy Based Hyperhidrosis Treatment.
U.S. Appl. No. 17/209,808, filed Mar. 23, 2021, Energy Based Skin Gland Treatment.
U.S. Appl. No. 11/163,151, filed Oct. 6, 2005, Method and System for Noninvasive Face Lifts and Deep Tissue Tightening.
U.S. Appl. No. 13/444,336, filed Apr. 11, 2012, Treatment of Sub-Dermal Regions for Cosmetic Effects.
U.S. Appl. No. 13/679,430, filed Nov. 16, 2012, Ultrasound Treatment of Sub-Dermal Tissue for Cosmetic Effects.
U.S. Appl. No. 13/924,376, filed Jun. 21, 2013, Noninvasive Tissue Tightening for Cosmetic Effects.
U.S. Appl. No. 13/924,355, filed Jun. 21, 2013, Noninvasive Aesthetic Treatment for Tightening Tissue.
U.S. Appl. No. 13/924,323, filed Jun. 21, 2013, Energy-Based Tissue Tightening.
U.S. Appl. No. 14/200,852, filed Mar. 7, 2014, Noninvasive Tissue Tightening System.
U.S. Appl. No. 14/200,961, filed Mar. 7, 2014, Energy-Based Tissue Tightening System.
U.S. Appl. No. 16/543,137, filed Aug. 16, 2019, Noninvasive Tissue Tightening System.
U.S. Appl. No. 12/028,636, filed Feb. 8, 2008, Method and System for Noninvasive Face Lifts and Deep Tissue Tightening.
U.S. Appl. No. 13/964,820, filed Aug. 12, 2013, Methods for Noninvasive Skin Tightening.
U.S. Appl. No. 14/201,256, filed Mar. 7, 2014, System for Noninvasive Skin Tightening.
U.S. Appl. No. 15/098,139, filed Apr. 13, 2016, System and Method for Noninvasive Skin Tightening.
U.S. Appl. No. 15/958,939, filed Apr. 20, 2018, System and Method for Noninvasive Skin Tightening.
U.S. Appl. No. 16/698,122, filed Nov. 27, 2019, System and Method for Noninvasive Skin Tightening.
U.S. Appl. No. 17/209,912, filed Mar. 23, 2021, System and Method for Noninvasive Skin Tightening.
U.S. Appl. No. 14/685,390, filed Apr. 13, 2015, Energy-Based Tissue Tightening System.
U.S. Appl. No. 11/163,150, filed Oct. 6, 2005, Method and System for Photoaged Tissue.
U.S. Appl. No. 13/230,498, filed Sep. 12, 2011, Method and System for Photoaged Tissue.
U.S. Appl. No. 14/169,709, filed Jan. 31, 2014, Methods for Treating Skin Laxity.
U.S. Appl. No. 14/692,114, filed Apr. 21, 2015, Systems for Treating Skin Laxity.
U.S. Appl. No. 15/248,407, filed Aug. 26, 2016, Systems for Treating Skin Laxity.
U.S. Appl. No. 15/625,700, filed Jun. 16, 2017, Systems for Treating Skin Laxity.
U.S. Appl. No. 15/821,070, filed Nov. 22, 2017, Ultrasound Probe for Treating Skin Laxity.
U.S. Appl. No. 15/996,255, filed Jun. 1, 2018, Ultrasound Probe for Treating Skin Laxity.
U.S. Appl. No. 16/284,907, filed Feb. 25, 2019, Ultrasound Probe for Treating Skin Laxity.
U.S. Appl. No. 16/797,362, filed Feb. 21, 2020, Ultrasound Probe for Treating Skin Laxity.
U.S. Appl. No. 17/127,721, filed Dec. 18, 2020, Ultrasound Probe for Treating Skin Laxity.
U.S. Appl. No. 11/163,176, filed Oct. 7, 2005, Method and System for Treating Blood Vessel Disorders.
U.S. Appl. No. 13/601,742, filed Aug. 31, 2012, Method and System for Treating Blood Vessel Disorders.
U.S. Appl. No. 12/574,512, filed Oct. 6, 2009, Method and System for Treating Stretch Marks.
U.S. Appl. No. 14/554,668, filed Nov. 26, 2014, Method and System for Treating Stretch Marks.
U.S. Appl. No. 15/260,825, filed Sep. 12, 2016, Method and System for Ultrasound Treatment of Skin.
U.S. Appl. No. 15/625,818, filed Jun. 16, 2017, Method and System for Ultrasound Treatment of Skin.
U.S. Appl. No. 15/829,182, filed Dec. 1, 2017, Ultrasound Probe for Treatment of Skin.
U.S. Appl. No. 15/996,263, filed Jun. 1, 2018, Ultrasound Probe for Treatment of Skin.
U.S. Appl. No. 16/284,920, filed Feb. 25, 2019, Ultrasound Probe for Treatment of Skin.
U.S. Appl. No. 16/797,387, filed Feb. 21, 2020, Ultrasound Probe for Treatment of Skin.
U.S. Appl. No. 11/857,989, filed Sep. 19, 2007, Method and System for Treating Muscle, Tendon, Ligament and Cartilage Tissue.
U.S. Appl. No. 13/494,856, filed Jun. 12, 2012, Method and System for Treating Muscle, Tendon, Ligament and Cartilage Tissue.
U.S. Appl. No. 13/835,635, filed Mar. 15, 2013, Methods for Face and Neck Lifts.
U.S. Appl. No. 13/965,741, filed Aug. 13, 2013, Methods for Preheating Tissue for Cosmetic Treatment of the Face and Body.
U.S. Appl. No. 14/740,092, filed Jun. 15, 2015, Methods for Rejuvenating Skin by Heating Tissue for Cosmetic Treatment of the Face and Body.
U.S. Appl. No. 15/862,400, filed Jan. 4, 2018, Rejuvenating Skin by Heating Tissue for Cosmetic Treatment of the Face and Body.
U.S. Appl. No. 16/409,678, filed May 10, 2019, Rejuvenating Skin by Heating Tissue for Cosmetic Treatment of the Face and Body.
U.S. Appl. No. 17/081,754, filed Oct. 27, 2020, Rejuvenating Skin by Heating Tissue for Cosmetic Treatment of the Face and Body.
U.S. Appl. No. 14/628,198, dated Feb. 20, 2015, System and Method for Treating Cartilage and Injuries to Joints and Connective Tissue.
U.S. Appl. No. 14/554,571, filed Nov. 26, 2014, Methods for Face and Neck Lifts.
U.S. Appl. No. 15/248,454, filed Aug. 26, 2016, Methods for Face and Neck Lifts.
U.S. Appl. No. 16/049,293, filed Jul. 30, 2018, Methods for Face and Neck Lifts.
U.S. Appl. No. 16/697,970, filed Nov. 27, 2019, Methods for Lifting Skin Tissue.
U.S. Appl. No. 12/954,484, filed Nov. 24, 2010, Methods and Systems for Generating Thermal Bubbles for Improved Ultrasound Imaging and Therapy.
U.S. Appl. No. 12/350,383, filed Jan. 8, 2009, Method and System for Treating Acne and Sebaceous Glands.
U.S. Appl. No. 12/116,845, filed May 7, 2008, Method and System for Combined Energy Profile.
U.S. Appl. No. 14/643,749, filed Mar. 10, 2015, Method and System for Combined Energy Profile.
U.S. Appl. No. 08/766,083, filed Dec. 16, 1996, Method and Apparatus for Surface Ultrasound Imaging.
U.S. Appl. No. 09/113,227, filed Jul. 10, 1998, Method and Apparatus for Three Dimensional Ultrasound Imaging.
U.S. Appl. No. 08/944,261, filed Oct. 6, 1997, Wideband Acoustic Transducer.
U.S. Appl. No. 09/434,078, filed Nov. 5, 1999, Method and Apparatus for Three Dimensional Ultrasound Imaging.
U.S. Appl. No. 09/523,890, filed Mar. 13, 2000, Method and Apparatus for Three Dimensional Ultrasound Imaging.
U.S. Appl. No. 09/419,543, filed Oct. 18, 1999, Peripheral Ultrasound Imaging System.
U.S. Appl. No. 09/750,816, filed Dec. 28, 2000, Visual Imaging System for Ultrasonic Probe.
U.S. Appl. No. 10/358,110, filed Feb. 4, 2003, Visual Imaging System for Ultrasonic Probe.
U.S. Appl. No. 11/380,161, filed Apr. 25, 2006, Method and System for Enhancing Computer Peripheral Safety.
U.S. Appl. No. 11/554,272, filed Oct. 30, 2006, Visual Imaging System for Ultrasonic Probe.
U.S. Appl. No. 13/071,298, dated Mar. 24, 2011, Visual Imaging System for Ultrasonic Probe.
U.S. Appl. No. 13/854,936, filed Mar. 25, 2013, Visual Imaging System for Ultrasonic Probe.
U.S. Appl. No. 12/509,254, filed Jul. 24, 2009, Method and System for Enhancing Computer Peripheral Safety.
U.S. Appl. No. 13/453,847, filed Apr. 23, 2012, Method and System for Enhancing Computer Peripheral Safety.
U.S. Appl. No. 11/538,794, filed Oct. 4, 2006, Ultrasound System and Method for Imaging and/or Measuring Displacement of Moving Tissue and Fluid.
U.S. Appl. No. 09/502,175, filed Feb. 10, 2000, Method and Apparatus for Safely Delivering Medicants to a Region of Tissue, Using Imaging, Therapy and Temperature Monitoring.
U.S. Appl. No. 08/943,728, filed Oct. 3, 1997, Method and Apparatus for Safely Delivering Medicants to a Region of Tissue Using Ultrasound.
U.S. Appl. No. 12/415,945, filed Mar. 31, 2009, Method and System for Noninvasive Mastopexy.
U.S. Appl. No. 11/163,155, filed Oct. 6, 2005, Method and System for Noninvasive Mastopexy.
U.S. Appl. No. 11/163,154, filed Oct. 6, 2005, Method and System for Treatment of Cellulite.
U.S. Appl. No. 13/356,405, filed Jan. 23, 2012, Method and System for Treatment of Cellulite.
U.S. Appl. No. 13/789,562, filed Mar. 7, 2013, Method and System for Ultrasound Treatment of Fat.
U.S. Appl. No. 14/164,598, filed Jan. 27, 2013, Method for Fat and Cellulite Reduction.
U.S. Appl. No. 14/550,720, filed Nov. 21, 2014, System and Method for Fat and Cellulite Reduction.
U.S. Appl. No. 15/041,829, filed Feb. 11, 2016, System and Method for Fat and Cellulite Reduction.
U.S. Appl. No. 15/374,918, filed Dec. 9, 2016, System and Method for Fat and Cellulite Reduction.
U.S. Appl. No. 15/650,246, filed Jul. 14, 2017, System and Method for Fat and Cellulite Reduction.
U.S. Appl. No. 15/821,281, filed Nov. 22, 2017, Ultrasound Probe for Fat and Cellulite Reduction.
U.S. Appl. No. 15/996,295, filed Jun. 1, 2018, Ultrasound Probe for Fat and Cellulite Reduction.
U.S. Appl. No. 16/272,453, filed Feb. 11, 2019, Ultrasound Probe for Tissue Treatment.
U.S. Appl. No. 16/794,717, filed Feb. 19, 2020, Ultrasound Probe for Tissue Treatment.
U.S. Appl. No. 17/127,705, filed Dec. 18, 2020, Ultrasound Probe for Tissue Treatment.
U.S. Appl. No. 11/738,682, filed Apr. 23, 2007, Method and System for Non-Ablative Acne Treatment and Prevention.
U.S. Appl. No. 12/116,810, filed May 7, 2008, Methods and Systems for Modulating Medicants Using Acoustic Energy.
U.S. Appl. No. 12/116,828, filed May 7, 2008, Methods and Systems for Coupling and Focusing Acoustic Energy Using a Coupler Member.
U.S. Appl. No. 12/646,609, filed Dec. 23, 2009, Methods and System for Fat Reduction and/or Cellulite Treatment.
U.S. Appl. No. 14/192,520, filed Feb. 27, 2014, Energy Based Fat Reduction.
U.S. Appl. No. 14/550,772, filed Nov. 21, 2014, Energy Based Fat Reduction.
U.S. Appl. No. 15/401,804, filed Feb. 11, 2016, Energy Based Fat Reduction.
U.S. Appl. No. 15/380,267, filed Dec. 15, 2016, Energy Based Fat Reduction.
U.S. Appl. No. 15/650,525, filed Jul. 18, 2017, Energy Based Fat Reduction.
U.S. Appl. No. 15/829,175, filed Dec. 1, 2017, Energy Based Fat Reduction.
U.S. Appl. No. 15/996,249, filed Jun. 1, 2018, Energy Based Fat Reduction.
U.S. Appl. No. 16/272,427, filed Feb. 11, 2019, Energy Based Fat Reduction.
U.S. Appl. No. 16/794,701, filed Feb. 19, 2020, Energy Based Fat Reduction.
U.S. Appl. No. 17/127,691, filed Dec. 18, 2020, Energy Based Fat Reduction.
U.S. Appl. No. 13/291,312, filed Nov. 11, 2011, Devices and Methods for Acoustic Shielding.
U.S. Appl. No. 14/487,504, filed Sep. 16, 2014, Devices and Methods for Acoustic Shielding.
U.S. Appl. No. 13/136,538, filed Aug. 2, 2011, Systems and Methods for Treating Acute and/or Chronic Injuries in Soft Tissue.
U.S. Appl. No. 13/136,542, filed Aug. 2, 2011, System and Method for Treating Cartilage.
U.S. Appl. No. 13/163,541, filed Aug. 2, 2011, Methods and Systems for Treating Plantar Fascia.
U.S. Appl. No. 13/136,544, filed Aug. 2, 2011, Systems and Methods for Ultrasound Treatment.
U.S. Appl. No. 13/547,023, filed Jul. 11, 2012, Systems and Methods for Coupling an Ultrasound Source to Tissue.
U.S. Appl. No. 13/545,931, filed Jul. 10, 2012, Methods and Systems for Controlling Acoustic Energy Deposition Into a Medium.
U.S. Appl. No. 13/545,953, filed Jul. 10, 2012, Systems and Methods for Accelerating Healing of Implanted Material and/or Native Tissue.
U.S. Appl. No. 13/547,011, filed Jul. 11, 2012, Systems and Methods for Monitoring and Controlling Ultrasound Power Output and Stability.
U.S. Appl. No. 13/545,954, filed Jul. 10, 2012, Systems and Methods for Improving an Outside Appearance of Skin Using Ultrasound as an Energy Source.
U.S. Appl. No. 13/545,945, filed Jul. 10, 2012, Systems and Methods for Treating Injuries to Joints and Connective Tissue.
U.S. Appl. No. 13/545,929, filed Jul. 10, 2012, Methods and Systems for Ultrasound Treatment.
U.S. Appl. No. 13/863,249, filed Apr. 15, 2013, Systems for Cosmetic Treatment.
U.S. Appl. No. 13/863,281, filed Apr. 15, 2013, Methods for Non-invasive Cosmetic Treatment.
U.S. Appl. No. 14/847,626, filed Sep. 8, 2015, Systems for Cosmetic Treatment.
U.S. Appl. No. 13/863,362, filed Apr. 15, 2013, Thick Film Transducer Arrays.
U.S. Appl. No. 14/217,110, filed Mar. 17, 2014, Ultrasound Treatment Device and Method of Use.
U.S. Appl. No. 14/217,382, filed Mar. 17, 2014, Ultrasound Treatment Device and Method of Use.
U.S. Appl. No. 14/225,189, filed Mar. 25, 2014, Reflective Ultrasound Technology for Dermatological Treatments.
U.S. Appl. No. 15/345,908, filed Nov. 8, 2016, Reflective Ultrasound Technology for Dermatological Treatments.
U.S. Appl. No. 15/719,377, filed Sep. 28, 2017, Reflective Ultrasound Technology for Dermatological Treatments.
U.S. Appl. No. 14/270,859, filed May 6, 2014, Methods and Systems for Generating Thermal Bubbles for Improved Ultrasound Imaging and Therapy.
U.S. Appl. No. 14/679,494, filed Apr. 6, 2015, Methods and Systems for Generating Thermal Bubbles for Improved Ultrasound Imaging and Therapy.
U.S. Appl. No. 14/405,368, filed Dec. 3, 2014, Devices and Methods for Ultrasound Focal Depth Control.
U.S. Appl. No. 14/568,954, filed Dec. 12, 2014, System and Method for Cosmetic Enhancement of Lips.
U.S. Appl. No. 14/569,001, filed Dec. 12, 2014, System and Method for Non-Invasive Treatment With Improved Efficiency.
U.S. Appl. No. 14/600,782, filed Jan. 20, 2015, Methods and Systems for Controlling and Acoustic Energy Deposition in Various Media.
U.S. Appl. No. 14/738,420, filed Jun. 12, 2015, Systems and Methods for Fast Ultrasound Treatment.
U.S. Appl. No. 14/751,349, filed Jun. 26, 2015, Methods and Systems for Tattoo Removal.
U.S. Appl. No. 15/001,712, filed Jan. 20, 2016, Methods and Systems for Removal of a Targeted Tissue from a Body.
U.S. Appl. No. 15/001,621, filed Jan. 20, 2016, Methods and Systems for Removal of a Foreign Object from Tissue.
U.S. Appl. No. 15/059,773, filed Mar. 3, 2016, Methods and Systems for Material Transport Across an Impermeable or Semi-Permeable Membrane Via Artificially Created Microchannels.
U.S. Appl. No. 15/094,774, filed Apr. 8, 2016, System and Method for Increased Control of Ultrasound Treatments.
Related Publications (1)
Number Date Country
20210146166 A1 May 2021 US
Provisional Applications (1)
Number Date Country
60616753 Oct 2004 US
Continuations (12)
Number Date Country
Parent 16794717 Feb 2020 US
Child 17127705 US
Parent 16272453 Feb 2019 US
Child 16794717 US
Parent 15996295 Jun 2018 US
Child 16272453 US
Parent 15821281 Nov 2017 US
Child 15996295 US
Parent 15650246 Jul 2017 US
Child 15821281 US
Parent 15374918 Dec 2016 US
Child 15650246 US
Parent 15041829 Feb 2016 US
Child 15374918 US
Parent 14550720 Nov 2014 US
Child 15041829 US
Parent 14164598 Jan 2014 US
Child 14550720 US
Parent 13789562 Mar 2013 US
Child 14164598 US
Parent 13356405 Jan 2012 US
Child 13789562 US
Parent 11163154 Oct 2005 US
Child 13356405 US